{"content":"<li class=\"n-box-item date-title\" data-end=\"1546664399\" data-start=\"1546578000\" data-txt=\"Monday, December 23, 2019\">Friday, January  4, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3420838\" data-ts=\"1546644281\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PCG\" target=\"_blank\">PCG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420838-pg-and-e-mulls-bankruptcy-reuters\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PG&amp;E mulls bankruptcy - Reuters</a></h4><ul><li>PG&amp;E (NYSE:<a href='https://seekingalpha.com/symbol/PCG' title='PG&E Corporation'>PCG</a>) <font color=\"red\">-26.2%</font> after-hours following a Reuters report that it is <a href=\"https://www.reuters.com/article/us-pg-e-us-bankruptcy-exclusive/exclusive-california-utility-pge-explores-bankruptcy-filing-sources-idUSKCN1OY225?il=0\" target=\"_blank\">considering filing for bankruptcy protection</a> for some or all of its businesses, as it faces billions of dollars in potential liabilities related to California wildfires in 2017-18.</li><li>PG&amp;E is exploring the move as a contingency, in part because it could take a significant Q4 financial charge related to liabilities from the catastrophic fires, according to the report.</li><li>A bankruptcy filing reportedly is not PG&amp;E's preference for addressing the liabilities, but the preparations could put pressure on California politicians hoping the company can avoid such an outcome.</li><li>Edison International (NYSE:<a href='https://seekingalpha.com/symbol/EIX' title='Edison International'>EIX</a>), suffering its own strains from fires in the state, <font color=\"red\">-5.8%</font> after-hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420838\" data-linked=\"PG&amp;E mulls bankruptcy - Reuters\" data-tweet=\"$PCG $PCG $EIX - PG&amp;E mulls bankruptcy - Reuters https://seekingalpha.com/news/3420838-pg-and-e-mulls-bankruptcy-reuters?source=tweet\" data-url=\"https://seekingalpha.com/news/3420838-pg-and-e-mulls-bankruptcy-reuters\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>244&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420836\" data-ts=\"1546643697\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SDT\" target=\"_blank\">SDT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420836-sandridge-mississippian-trusts-get-nyse-continued-listing-standards-notice\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SandRidge Mississippian trusts get NYSE continued listing standards notice</a></h4><ul><li>SandRidge Mississippian Trust I (NYSE:<a href='https://seekingalpha.com/symbol/SDT' title='SandRidge Mississippian Trust I'>SDT</a>) and SandRidge Mississippian Trust II (NYSE:<a href='https://seekingalpha.com/symbol/SDR' title='SandRidge Mississippian Trust II'>SDR</a>) say they received notice from the NYSE regarding their continued listing status (<a href=\"https://seekingalpha.com/pr/17370894-sandridge-mississippian-trust-announces-receipt-notice-nyse-regarding-continued-listing\" target=\"_blank\">I</a>, <a href=\"https://seekingalpha.com/pr/17370896-sandridge-mississippian-trust-ii-announces-receipt-notice-nyse-regarding-continued-listing\" target=\"_blank\">II</a>).</li><li>The Trusts say they can avoid delisting if, during the six-month period following receipt of the NYSE notice, on the last trading-day of any calendar month, their shares have a closing price and 30 trading-day average closing price of at least $1.00.</li><li>SDT and SDR say they do not plan a reverse split of the units or other action in an effort to affect the trading price.</li><li>SDT <font color=\"green\">+4.4%</font>, SDR <font color=\"red\">-2.6%</font> after-hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420836\" data-linked=\"SandRidge Mississippian trusts get NYSE continued listing standards notice\" data-tweet=\"$SDT $SDT $SDR - SandRidge Mississippian trusts get NYSE continued listing standards notice https://seekingalpha.com/news/3420836-sandridge-mississippian-trusts-get-nyse-continued-listing-standards-notice?source=tweet\" data-url=\"https://seekingalpha.com/news/3420836-sandridge-mississippian-trusts-get-nyse-continued-listing-standards-notice\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420831\" data-ts=\"1546642387\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTRA\" target=\"_blank\">NTRA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420831-petx-zagg-irwd-and-insm-among-notable-after-hour-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PETX, ZAGG, IRWD and INSM among notable after hour movers</a></h4><ul><li><b>Top Gainers:</b> <a href='https://seekingalpha.com/symbol/NTRA' title='Natera'>NTRA</a> <font color=\"green\">+38.8%</font>. <a href='https://seekingalpha.com/symbol/INSM' title='Insmed, Inc.'>INSM</a> <font color=\"green\">+22.5%</font>. <a href='https://seekingalpha.com/symbol/PETX' title='Aratana Therapeutics'>PETX</a> <font color=\"green\">+9%</font>. <a href='https://seekingalpha.com/symbol/AKBA' title='Akebia Therapeutics, Inc.'>AKBA</a> <font color=\"green\">+6.8%</font>. <a href='https://seekingalpha.com/symbol/ZAGG' title='ZAGG Inc'>ZAGG</a> <font color=\"green\">+4.1%</font>.</li><li><b>Top Losers:</b> <a href='https://seekingalpha.com/symbol/IRWD' title='Ironwood Pharmaceuticals, Inc.'>IRWD</a> <font color=\"red\">-10.2%</font>. <a href='https://seekingalpha.com/symbol/RGNX' title='REGENXBIO'>RGNX</a> <font color=\"red\">-9.8%</font>. <a href='https://seekingalpha.com/symbol/SGRY' title='Surgery Partners, Inc.'>SGRY</a> <font color=\"red\">-9.7%</font>. <a href='https://seekingalpha.com/symbol/ANGO' title='AngioDynamics, Inc.'>ANGO</a> <font color=\"red\">-9.7%</font>. <a href='https://seekingalpha.com/symbol/CDNA' title='CareDx'>CDNA</a> <font color=\"red\">-9.3%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420831\" data-linked=\"PETX, ZAGG, IRWD and INSM among notable after hour movers\" data-tweet=\"$NTRA $NTRA $INSM - PETX, ZAGG, IRWD and INSM among notable after hour movers https://seekingalpha.com/news/3420831-petx-zagg-irwd-and-insm-among-notable-after-hour-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3420831-petx-zagg-irwd-and-insm-among-notable-after-hour-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420832\" data-ts=\"1546642362\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GTN\" target=\"_blank\">GTN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420832-gray-television-ends-sales-representation-deals-raycom-stations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gray Television ends sales representation deals at Raycom stations</a></h4><ul>   <li>With its <a href=\"https://seekingalpha.com/news/3420313-gray-television-closes-3_6b-raycom-acquisition\" target=\"_blank\">$3.6B acquisition of Raycom</a> complete, Gray Television (NYSE:<a href='https://seekingalpha.com/symbol/GTN' title='Gray Television, Inc.'>GTN</a>) is <a href=\"https://seekingalpha.com/pr/17370951-gray-handle-national-sales-house-former-raycom-television-stations\" target=\"_blank\">terminating national ad sales representation contracts</a> covering the involved stations.</li>    <li>Beginning Feb. 25, the former Raycom stations will join legacy Gray stations in handling all business directly with buyers, the company says.</li>    <li>\"For the past few years, Gray\u2019s legacy television stations have successfully managed national advertising sales directly with national buyers, just as these stations have always dealt directly with their local and regional clients,\" Gray says.</li>    <li>\u201cRaycom Media has had a long and mutually beneficial relationship with Cox Reps,\" says co-CEO Pat LaPlatney, who joined via the acquisition. \"We nevertheless believe that Gray has the systems and experience that will allow the former Raycom stations to take national sales in-house in a manner that will make those transactions more efficient for all parties.\"</li><li>Gray's taking on termination fees of $27.6M to be reflected in Q1 broadcast expenses; it believes average annual expense savings will be $11M.</li>    <li><a href='https://seekingalpha.com/symbol/GTN' title='Gray Television, Inc.'>GTN</a> is <font color=\"red\">3.4% lower</font> after hours; it closed <font color=\"green\">up 3.5%</font> during the regular session.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3420832\" data-linked=\"Gray Television ends sales representation deals at Raycom stations\" data-tweet=\"$GTN - Gray Television ends sales representation deals at Raycom stations https://seekingalpha.com/news/3420832-gray-television-ends-sales-representation-deals-raycom-stations?source=tweet\" data-url=\"https://seekingalpha.com/news/3420832-gray-television-ends-sales-representation-deals-raycom-stations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:52 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420828\" data-ts=\"1546640567\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SEM\" target=\"_blank\">SEM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420828-select-medical-issues-2019-guidance-sharesminus-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Select Medical issues 2019 guidance; shares -5%</a></h4><ul>   <li>Long-term hospital operator Select Medical Holdings (NYSE:<a href='https://seekingalpha.com/symbol/SEM' title='Select Medical Holdings Corporation'>SEM</a>) is <font color=\"red\">5% lower</font> in postmarket trading after <a href=\"https://seekingalpha.com/pr/17370930-select-medical-holdings-corporation-announces-business-outlook-2019\" target=\"_blank\">announcing 2019 guidance</a>.</li>    <li>It expects full-year net operating revenues of $5.2B-$5.4B, vs. consensus for $5.32B, along with EBITDA of $660M-$700M.</li>    <li>It's forecasting fully diluted income per common share for the year of $0.97-$1.13. Consensus of eight analysts has the company drawing EPS of $1.26 for the year.</li><li>#JPM19</li> </ul><div class=\"tiny-share-widget\" data-id=\"3420828\" data-linked=\"Select Medical issues 2019 guidance; shares -5%\" data-tweet=\"$SEM - Select Medical issues 2019 guidance; shares -5% https://seekingalpha.com/news/3420828-select-medical-issues-2019-guidance-sharesminus-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3420828-select-medical-issues-2019-guidance-sharesminus-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:22 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420814\" data-ts=\"1546638583\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMRN\" target=\"_blank\">AMRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420814-amarin-off-7-after-hours-on-soft-2019-outlook-for-vascepa\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amarin off 7% after hours on soft 2019 outlook for Vascepa</a></h4><ul><li>Amarin (NASDAQ:<a href='https://seekingalpha.com/symbol/AMRN' title='Amarin Corporation PLC'>AMRN</a>) is down <font color=\"red\">7%</font> after hours on the heels of its <a href=\"https://seekingalpha.com/pr/17370901-amarin-provides-preliminary-2018-results-2019-outlook\" target=\"_blank\">announcement </a>of preliminary 2018 results and 2019 forecast, information that will be presented next week at JPM19.</li><li>Vascepa (icosapent ethyl) sales in Q4 2018 were $72M - 76M, above consensus of $69.4M. 2018 sales were $224M - 228M, above consensus of $221.4M.</li><li>Its outlook for 2019 is ~$350M, below consensus of $417.5M. It does not expect managed care coverage to change much from last year.</li><li>The company plans to file a supplemental marketing application in the U.S. seeking approval for a cardioprotective claim for Vascepa this quarter. It does not expect the new indication, if approved, to impact its 2019 forecast.</li><li>It plans to spend an additional $50M - 75M this year to purchase additional inventory of product to support a revenue rate of ~$700M this year.</li><li>Salesforce now numbers 400, up from 150 last year.</li><li>#JPM19</li></ul><div class=\"tiny-share-widget\" data-id=\"3420814\" data-linked=\"Amarin off 7% after hours on soft 2019 outlook for Vascepa\" data-tweet=\"$AMRN - Amarin off 7% after hours on soft 2019 outlook for Vascepa https://seekingalpha.com/news/3420814-amarin-off-7-after-hours-on-soft-2019-outlook-for-vascepa?source=tweet\" data-url=\"https://seekingalpha.com/news/3420814-amarin-off-7-after-hours-on-soft-2019-outlook-for-vascepa\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>111&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420810\" data-ts=\"1546637571\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INSM\" target=\"_blank\">INSM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420810-insmed-up-17-after-hours-on-arikayce-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Insmed up 17% after hours on Arikayce update</a></h4><ul><li>Insmed (NASDAQ:<a href='https://seekingalpha.com/symbol/INSM' title='Insmed, Inc.'>INSM</a>) is up <font color=\"green\">17%</font> after hours on the heels of its <a href=\"https://seekingalpha.com/pr/17370882-insmed-provides-update-arikayce-amikacin-liposome-inhalation-suspension-u-s-launch-outlines\" target=\"_blank\">update </a>on the U.S. commercial launch of ARIKAYCE (amikacin liposome inhalation suspension), information that will be presented at JPM19 next Wednesday, January 9.</li><li>On a preliminary basis, Q4 sales were ~$9.8M. Final results will be released on Friday, February 22.</li><li>It expects to complete the design and protocol in H1 for a confirmatory study to support full U.S. approval of ARIKAYCE for first-line Mycobacterium avium complex &#40;MAC&#41; lung disease. The FDA <a href=\"https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm622048.htm\" target=\"_blank\">approved </a>the product in September 2018 under its Limited Population Pathway for Antibacterial and Antifungal Drugs.</li><li>Marketing applications will be filed in Europe mid-year and Japan in H1 2020.</li><li>Enrollment in a Phase 2 clinical trial, WILLOW, evaluating INS1007 in non-cystic fibrosis bronchiectasis should be completed mid-year.</li><li>#JPM19</li></ul><div class=\"tiny-share-widget\" data-id=\"3420810\" data-linked=\"Insmed up 17% after hours on Arikayce update\" data-tweet=\"$INSM - Insmed up 17% after hours on Arikayce update https://seekingalpha.com/news/3420810-insmed-up-17-after-hours-on-arikayce-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3420810-insmed-up-17-after-hours-on-arikayce-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420806\" data-ts=\"1546636717\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RGLS\" target=\"_blank\">RGLS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420806-regulus-up-8-after-hours-on-positive-preclinical-data-on-rgls4326\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Regulus up 8% after hours on positive preclinical data on RGLS4326</a></h4><ul><li>Nano cap Regulus Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/RGLS' title='Regulus Therapeutics'>RGLS</a>) is up <font color=\"green\">8%</font> after hours in response to its <a href=\"https://seekingalpha.com/pr/17370881-regulus-announces-preliminary-results-planned-interim-data-analysis-rgls4326-new-mouse\" target=\"_blank\">announcement </a>of positive results from a new mouse toxicity study of RGLS4326, a candidate for autosomal dominant polycystic kidney disease &#40;ADPKD&#41;.</li><li>After 13 weeks of dosing, no adverse events or other significant findings were observed across all doses tested. The company plans to restart a Phase 1 trial.</li><li>Last summer, it suspended the Phase 1 after seeing \"unexpected observations\" in the first mouse study that was being conducted in parallel. The company believes the unexpected results were due to technical issues at the contract research organization running the study.</li><li>RGLS4326 is a novel oligonucleotide that the company says preferentially targets the kidney by inhibiting an RNA gene called miR-17.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420806\" data-linked=\"Regulus up 8% after hours on positive preclinical data on RGLS4326\" data-tweet=\"$RGLS - Regulus up 8% after hours on positive preclinical data on RGLS4326 https://seekingalpha.com/news/3420806-regulus-up-8-after-hours-on-positive-preclinical-data-on-rgls4326?source=tweet\" data-url=\"https://seekingalpha.com/news/3420806-regulus-up-8-after-hours-on-positive-preclinical-data-on-rgls4326\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420800\" data-ts=\"1546636052\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GE\" target=\"_blank\">GE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420800-report-apollo-considering-bid-for-ges-jet-leasing-business\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Report: Apollo considering bid for GE&#39;s jet leasing business</a></h4><ul><li>General Electric (NYSE:<a href='https://seekingalpha.com/symbol/GE' title='General Electric'>GE</a>) <font color=\"green\">+2.7%</font> after-hours on headlines that Apollo Global Management (NYSE:<a href='https://seekingalpha.com/symbol/APO' title='Apollo Global Management, LLC'>APO</a>) is considering <a href=\"https://twitter.com/cfromhertz/status/1081294584968343553\" target=\"_blank\">making a bid for the company's jet leasing business</a>, which is said to be worth as much as $40B.</li><li><a href=\"https://www.bloomberg.com/news/articles/2019-01-04/apollo-considers-bid-for-ge-jet-leasing-business-ge-stock-rises?srnd=premium\" target=\"_blank\">Bloomberg reports</a> APO has met with lenders to secure ~$30B in financing to purchase all or part of GE Capital Aviation Services, as potential buyers circle one of GE\u2019s crown jewels.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420800\" data-linked=\"Report: Apollo considering bid for GE&#39;s jet leasing business\" data-tweet=\"$GE $GE $APO - Report: Apollo considering bid for GE&#39;s jet leasing business https://seekingalpha.com/news/3420800-report-apollo-considering-bid-for-ges-jet-leasing-business?source=tweet\" data-url=\"https://seekingalpha.com/news/3420800-report-apollo-considering-bid-for-ges-jet-leasing-business\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>193&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420797\" data-ts=\"1546635892\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PCG\" target=\"_blank\">PCG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420797-pg-and-e-seeking-board-changes-reviewing-structural-options\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PG&amp;E seeking board changes, reviewing structural options</a></h4><ul><li>PG&amp;E (<a href='https://seekingalpha.com/symbol/PCG' title='PG&E Corporation'>PCG</a> <font color='green'>+1.9%</font>) says it is conducting a \"<a href=\"https://seekingalpha.com/pr/17370849-pg-and-e-board-committed-change\" target=\"_blank\">board refreshment process</a>\" that includes a search for new directors at its holding company and its Pacific Gas and Electric utility subsidiary.</li><li>The company says it is working with a leading search firm to identify new directors and is currently interviewing several candidates.</li><li>PG&amp;E says it reviewing structural options to best position it to implement         necessary changes while meeting customer and operational needs, in the wake of November's deadly wildfires in northern California.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420797\" data-linked=\"PG&amp;E seeking board changes, reviewing structural options\" data-tweet=\"$PCG - PG&amp;E seeking board changes, reviewing structural options https://seekingalpha.com/news/3420797-pg-and-e-seeking-board-changes-reviewing-structural-options?source=tweet\" data-url=\"https://seekingalpha.com/news/3420797-pg-and-e-seeking-board-changes-reviewing-structural-options\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420791\" data-ts=\"1546634571\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHLDQ\" target=\"_blank\">SHLDQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420791-cnbc-lampert-s-bid-to-save-sears-appears-to-come-up-short\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CNBC: Lampert\u2019s bid to save Sears appears to come up short</a></h4><ul><li>Sears (<a href='https://seekingalpha.com/symbol/SHLDQ' title='Sears Holdings Corporation'>OTCPK:SHLDQ</a> <font color='red'>-13.3%</font>) believes Eddie Lampert's last-ditch bid to save the company has <a href=\"https://www.cnbc.com/2019/01/04/eddie-lamperts-bid-for-sears-may-be-short-may-liquidate-without-fix.html\" target=\"_blank\">fallen short</a>, CNBC reports.</li><li><a href=\"https://seekingalpha.com/news/3419636-lampert-makes-last-ditch-bid-save-sears-4_4b-bid\" target=\"_blank\">Lampert\u2019s $4.4B offer</a> through his ESL Investments hedge fund is the only bid that could keep Sears going in its entirety; without a deal, the company could liquidate.</li><li>Sears' advisors have until 4:00 p.m. ET today to decide whether Lampert\u2019s bid is viable.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420791\" data-linked=\"CNBC: Lampert\u2019s bid to save Sears appears to come up short\" data-tweet=\"$SHLDQ - CNBC: Lampert\u2019s bid to save Sears appears to come up short https://seekingalpha.com/news/3420791-cnbc-lampert-s-bid-to-save-sears-appears-to-come-up-short?source=tweet\" data-url=\"https://seekingalpha.com/news/3420791-cnbc-lampert-s-bid-to-save-sears-appears-to-come-up-short\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>108&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420790\" data-ts=\"1546634352\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RCUS\" target=\"_blank\">RCUS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420790-arcus-bio-down-14-on-coo-departure\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Arcus Bio down 14% on COO departure</a></h4><ul><li>Thinly traded micro cap Arcus Biosciences (<a href='https://seekingalpha.com/symbol/RCUS' title='Arcus Biosciences'>RCUS</a> <font color=\"red\">-13.9%</font>) is down on almost double normal, albeit on turnover of only 439K shares, in response to the <a href=\"https://seekingalpha.com/pr/17370542-arcus-biosciences-announces-transition-chief-financial-operating-officer\" target=\"_blank\">announced exit</a> of COO and CFO Jennifer Jarrett to \"pursue an opportunity\" at a transportation and technology company. She plans to depart on January 11 but has agreed to serve in a consulting role to ensure a smooth transition.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420790\" data-linked=\"Arcus Bio down 14% on COO departure\" data-tweet=\"$RCUS - Arcus Bio down 14% on COO departure https://seekingalpha.com/news/3420790-arcus-bio-down-14-on-coo-departure?source=tweet\" data-url=\"https://seekingalpha.com/news/3420790-arcus-bio-down-14-on-coo-departure\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420789\" data-ts=\"1546633871\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTWS\" target=\"_blank\">CTWS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420789-connecticut-water-sjw-lose-bid-to-reopen-review-of-proposed-merger\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Connecticut Water, SJW lose bid to reopen review of proposed merger</a></h4><ul><li>Connecticut Water (<a href='https://seekingalpha.com/symbol/CTWS' title='Connecticut Water Service, Inc.'>CTWS</a> <font color=\"red\">-4.4%</font>) sinks after its request to reopen the review of its proposed $1.1B buyout by California's SJW Group (<a href='https://seekingalpha.com/symbol/SJW' title='SJW Corp.'>SJW</a> <font color=\"green\">+2.4%</font>) is <a href=\"https://seekingalpha.com/pr/17370832-sjw-group-issues-statement-connecticut-public-utilities-regulatory-authority-ruling\" target=\"_blank\">denied</a> by the Connecticut Public Utilities Regulatory Authority.</li><li>The companies last month had offered various new commitments to state regulators,  who had preliminarily denied the proposed combination.</li><li>Eversource Energy (<a href='https://seekingalpha.com/symbol/ES' title='Eversource Energy'>ES</a> <font color=\"green\">+0.6%</font>), a spurned suitor in last year\u2019s bidding war for CTWS, had urged state regulators to stand by their  preliminary rejection.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420789\" data-linked=\"Connecticut Water, SJW lose bid to reopen review of proposed merger\" data-tweet=\"$CTWS $CTWS $SJW - Connecticut Water, SJW lose bid to reopen review of proposed merger https://seekingalpha.com/news/3420789-connecticut-water-sjw-lose-bid-to-reopen-review-of-proposed-merger?source=tweet\" data-url=\"https://seekingalpha.com/news/3420789-connecticut-water-sjw-lose-bid-to-reopen-review-of-proposed-merger\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420788\" data-ts=\"1546633079\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420788-trump-not-worried-apple-stock-company-should-build-in-u-s\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trump: Not worried about Apple stock; company should build in U.S.</a></h4><ul>   <li>President Trump's latest <a href=\"https://www.c-span.org/video/?456701-1/president-trump-confirms-shutdown-months-years\" target=\"_blank\">interchange with reporters</a> included new stock commentary, on news dominating the tech sector this week: He's not worried about a drop in Apple's (<a href=\"http://seekingalpha.com/symbol/AAPL\" target=\"_blank\">AAPL</a> <font color=\"green\">+3.7%</font>) stock price.</li>    <li>\"They've gone up hundreds of percent since I'm president,\" he says. \"Apple was at a number that was incredible and they're gonna be fine; Apple is a great company.\" (Apple shares are <font color=\"green\">up 26.7%</font> since Trump's inauguration, adjusting for dividends and splits.)</li>    <li>He is calling for them to move manufacturing to the U.S., however.</li>    <li>\"Don't forget this: Apple makes their product in China,\" he says. \"I told [CEO] Tim Cook ... make your product in the United States. Build those big beautiful plants that go on for miles, it seems.</li>    <li>\"China is the biggest beneficiary of Apple, more than us ... I want Apple to make their iPhones and all of the great things that they make in the United States, and that'll take place.\"</li><li>Previously: <a href=\"https://seekingalpha.com/news/3420157-apple-cuts-q1-revenue-guidance\" target=\"_blank\">Apple cuts Q1 revenue guidance</a> (Jan. 02 2019)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3420788\" data-linked=\"Trump: Not worried about Apple stock; company should build in U.S.\" data-tweet=\"$AAPL - Trump: Not worried about Apple stock; company should build in U.S. https://seekingalpha.com/news/3420788-trump-not-worried-apple-stock-company-should-build-in-u-s?source=tweet\" data-url=\"https://seekingalpha.com/news/3420788-trump-not-worried-apple-stock-company-should-build-in-u-s\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>389&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420787\" data-ts=\"1546632994\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420787-big-day-for-emerging-markets\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Big day for emerging markets</a></h4><ul><li>U.S. stocks were already set for a strong day, and then Fed Chair Jay Powell <a href=\"https://seekingalpha.com/news/3420721-powell-gives-averages-additional-boost\" target=\"_blank\">aided things by suggesting</a> the central bank is ready to quickly halt its tightening phase and even begin easing, if necessary.</li><li>That's helped send the S&amp;P 500 <font color=\"green\">soaring 3.25% </font>and the Nasdaq <font color=\"green\">4.1%</font>.</li><li>The prospect of eased U.S. monetary policy would also be good news for roughed up emerging markets, and the iShares MSCI Emerging Markets ETF (<a href='https://seekingalpha.com/symbol/EEM' title='iShares MSCI Emerging Markets ETF'>EEM</a> <font color='green'>+3.3%</font>) and Vanguard FTSE Emerging Markets (<a href='https://seekingalpha.com/symbol/VWO' title='Vanguard FTSE Emerging Markets ETF'>VWO</a> <font color='green'>+3.3%</font>) are responding.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420787\" data-linked=\"Big day for emerging markets\" data-tweet=\"$EEM $VWO - Big day for emerging markets https://seekingalpha.com/news/3420787-big-day-for-emerging-markets?source=tweet\" data-url=\"https://seekingalpha.com/news/3420787-big-day-for-emerging-markets\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420785\" data-ts=\"1546632660\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HON\" target=\"_blank\">HON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420785-honeywellplus-3-after-rbc-credit-suisse-upgrades\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Honeywell +3% after RBC, Credit Suisse upgrades</a></h4><ul><li>Honeywell (<a href='https://seekingalpha.com/symbol/HON' title='Honeywell International, Inc.'>HON</a> <font color='green'>+3.3%</font>) is higher after RBC Capital <a href=\"https://www.barrons.com/articles/honeywell-stock-is-stable-and-cheap-51546623779\" target=\"_blank\">upgrades</a> shares to Outperform from Sector Perform with a $148 price target, saying the spinoffs of Garrett Motion and Resideo Technologies have \"bolstered earnings quality and defensive mix.\"</li><li>The re-rated company has \"higher profitability, dampened cyclicality, stronger balance sheet, reduced legacy environmental/asbestos liabilities, and undivided attention on its core businesses,\" writes RBC's Deane Dray, who expects investors to reflect HON's <a href=\"https://thefly.com/thestreet/realmoney/index.php/HONid2843764/HON-Honeywell-upgraded-to-Outperform-from-Sector-Perform-at-RBC-Capital\" target=\"_blank\">shift up the \"quality curve.</a>\"</li><li>Dray also says HON has \"plenty of dry powder for M&amp;A, as [new CEO Darius Adamczyk] begins to execute his objective to transform the company to a Software-Industrial.\"</li><li>The RBC upgrade comes a day after Credit Suisse's John Walsh made HON one of his <a href=\"https://seekingalpha.com/news/3420255-credit-suisse-weighs-industrials\" target=\"_blank\">top industrial stock picks</a> for 2019, highlighting the company\u2019s strong balance sheet and above-average free cash flow generation.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420785\" data-linked=\"Honeywell +3% after RBC, Credit Suisse upgrades\" data-tweet=\"$HON - Honeywell +3% after RBC, Credit Suisse upgrades https://seekingalpha.com/news/3420785-honeywellplus-3-after-rbc-credit-suisse-upgrades?source=tweet\" data-url=\"https://seekingalpha.com/news/3420785-honeywellplus-3-after-rbc-credit-suisse-upgrades\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420784\" data-ts=\"1546632013\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WISA\" target=\"_blank\">WISA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420784-microcaps-mostly-among-tech-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Microcaps mostly among tech movers</a></h4><ul><li><strong>Gainers: </strong>Summit Wireless Technologies (<a href='https://seekingalpha.com/symbol/WISA' title='Summit Semiconductor Inc'>WISA</a>) <font color=\"green\">+19%</font>. FTE Networks (NYSEMKT:<a href='https://seekingalpha.com/symbol/FTNW' title='FTE Networks, Inc.'>FTNW</a>) <font color=\"green\">+19%</font>. GTT Communications (NYSE:<a href='https://seekingalpha.com/symbol/GTT' title='GTT Communications, Inc.'>GTT</a>) <font color=\"green\">+17%</font>. Inseego (NASDAQ:<a href='https://seekingalpha.com/symbol/INSG' title='Inseego Corp.'>INSG</a>) <font color=\"green\">+15%</font>. BSQUARE Corporation (NASDAQ:<a href='https://seekingalpha.com/symbol/BSQR' title='BSQUARE Corporation'>BSQR</a>) <font color=\"green\">+14%</font>.</li> <li><strong>Losers: </strong>Boxlight Corporation (NASDAQ:<a href='https://seekingalpha.com/symbol/BOXL' title='Boxlight'>BOXL</a>) <font color=\"red\">-14%</font>. Superconductor Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/SCON' title='Superconductor Technologies Inc.'>SCON</a>) <font color=\"red\">-6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3420784\" data-linked=\"Microcaps mostly among tech movers\" data-tweet=\"$WISA $WISA $FTNW - Microcaps mostly among tech movers https://seekingalpha.com/news/3420784-microcaps-mostly-among-tech-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3420784-microcaps-mostly-among-tech-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420782\" data-ts=\"1546631891\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FB\" target=\"_blank\">FB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420782-reuters-time-for-new-captain-facebook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Reuters: Time for new captain at Facebook?</a></h4><ul>   <li>It's <a href=\"https://www.breakingviews.com/considered-view/a-graying-facebook-will-require-a-different-leader/\" target=\"_blank\">time for new leadership</a> and even a new business model at Facebook (<a href=\"http://seekingalpha.com/symbol/FB\" target=\"_blank\">FB</a> <font color=\"green\">+4.2%</font>), Reuters' Jennifer Saba argues, saying that while Chairman/CEO Mark Zuckerberg is inseparable from the social network, his lack of perspective helped create its existential problems.</li>    <li>The choice is between stemming user losses by cleaning up its controversial content/policies or looking for new revenue streams, she argues.</li>    <li>A previous challenge (in 2012, addressing doubts it could move ads to mobile phones from PCs) was solved by Zuckerberg and COO Sheryl Sandberg -- without changing the model but doubling costs.</li>    <li>If that happens now, Saba suggests, opex would hit $50B and slower revenue growth would land at $68B; after taxes, profits of $15B would value Facebook (via current multiples) at $260B, a third less than at the end of November.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3420782\" data-linked=\"Reuters: Time for new captain at Facebook?\" data-tweet=\"$FB - Reuters: Time for new captain at Facebook? https://seekingalpha.com/news/3420782-reuters-time-for-new-captain-facebook?source=tweet\" data-url=\"https://seekingalpha.com/news/3420782-reuters-time-for-new-captain-facebook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>132&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420775\" data-ts=\"1546628249\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMID\" target=\"_blank\">AMID</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420775-american-midstream-partners-and-key-energy-services-among-energy-materials-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">American Midstream Partners and Key Energy Services among Energy/Materials gainers</a></h4><ul><li><b>Gainers: </b>American Midstream Partners (NYSE:<a href='https://seekingalpha.com/symbol/AMID' title='American Midstream Partners, LP'>AMID</a>) <font color=\"green\">+27%</font>. Key Energy Services (NYSE:<a href='https://seekingalpha.com/symbol/KEG' title='Key Energy Services, Inc.'>KEG</a>) <font color=\"green\">+19%</font>. Chaparral Energy (NYSE:<a href='https://seekingalpha.com/symbol/CHAP' title='Chaparral Energy Inc'>CHAP</a>) <font color=\"green\">+15%</font>. AK Steel Holding (NYSE:<a href='https://seekingalpha.com/symbol/AKS' title='AK Steel Holding Corp'>AKS</a>) <font color=\"green\">+13%</font>. Lilis Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/LLEX' title='Lilis Energy, Inc.'>LLEX</a>) <font color=\"green\">+13%</font>.</li><li><b>Losers: </b>Eldorado Gold (NYSE:<a href='https://seekingalpha.com/symbol/EGO' title='Eldorado Gold Corporation'>EGO</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420775\" data-linked=\"American Midstream Partners and Key Energy Services among Energy/Materials gainers\" data-tweet=\"$AMID $AMID $KEG - American Midstream Partners and Key Energy Services among Energy/Materials gainers https://seekingalpha.com/news/3420775-american-midstream-partners-and-key-energy-services-among-energy-materials-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3420775-american-midstream-partners-and-key-energy-services-among-energy-materials-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420772\" data-ts=\"1546625824\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EXPE\" target=\"_blank\">EXPE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420772-goldman-sachs-sees-big-bounce-for-expedia\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Goldman Sachs sees big bounce for Expedia</a></h4><ul> <li>Goldman Sachs expects a vibrant rally for Expedia (<a href='https://seekingalpha.com/symbol/EXPE' title='Expedia, Inc.'>EXPE</a> <font color='green'>+4.8%</font>) this year.</li> <li>\"While we're still generally cautious on the travel space given tight supply and healthy underlying demand, we believe TripAdvisor and Booking's recent ad spend rationalization puts Expedia in a better relative position,\" writes analyst Heath Terry.</li> <li>\"We believe we have seen evidence of this during recent periods where Expedia was able to drive bookings growth acceleration alongside leverage in ad spend,\" Terry adds.</li> <li>GS upgrades Expedia to a Buy rating from Neutral and assigns a price target of <a href=\"https://www.cnbc.com/2019/01/04/goldman-sachs-upgrades-expedia-to-buy-sees-nearly-30-percent-rally-.html\" target=\"_blank\">$140</a>, just a shade above the 52-week high of $139.77.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3420772\" data-linked=\"Goldman Sachs sees big bounce for Expedia\" data-tweet=\"$EXPE - Goldman Sachs sees big bounce for Expedia https://seekingalpha.com/news/3420772-goldman-sachs-sees-big-bounce-for-expedia?source=tweet\" data-url=\"https://seekingalpha.com/news/3420772-goldman-sachs-sees-big-bounce-for-expedia\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420766\" data-ts=\"1546625479\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RHHBY\" target=\"_blank\">RHHBY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420766-biotechs-lead-broad-market-advance-xbi-up-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biotechs lead broad market advance, XBI up 5%</a></h4><ul><li>Biotech and healthcare companies are enjoying robust buying in conjunction with the broad market. The SPDR S&amp;P Biotech ETF (<a href='https://seekingalpha.com/symbol/XBI' title='SPDR Biotech ETF'>XBI</a> <font color=\"green\">+5.1%</font>) is ahead of the major indexes, albeit on below-average volume.</li><li>Selected tickers: (<a href='https://seekingalpha.com/symbol/XLV' title='Health Care Select Sect SPDR ETF'>XLV</a> <font color=\"green\">+3.5%</font>)(<a href='https://seekingalpha.com/symbol/BIB' title='ProShares Ultra Nasdaq Biotechnology ETF'>BIB</a> <font color=\"green\">+10.7%</font>)(<a href='https://seekingalpha.com/symbol/PJP' title='Invesco Dynamic Pharmaceuticals Portfolio ETF'>PJP</a> <font color=\"green\">+3.7%</font>)(<a href='https://seekingalpha.com/symbol/VHT' title='Vanguard Health Care ETF'>VHT</a> <font color=\"green\">+3.8%</font>)(<a href='https://seekingalpha.com/symbol/IYH' title='iShares U.S. Healthcare ETF'>IYH</a> <font color=\"green\">+3.7%</font>)(<a href='https://seekingalpha.com/symbol/IBB' title='iShares Nasdaq Biotechnology ETF'>IBB</a> <font color=\"green\">+5.4%</font>)(<a href='https://seekingalpha.com/symbol/RHHBY' title='Roche Holding Ltd ADR'>OTCQX:RHHBY</a> <font color=\"green\">+1.1%</font>)(<a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a> <font color=\"green\">+3.1%</font>)(<a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a> <font color=\"green\">+4.7%</font>)(<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a> <font color=\"green\">+2.6%</font>)(<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a> <font color=\"green\">+4.9%</font>)(<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co Inc.'>MRK</a> <font color=\"green\">+3.2%</font>)(<a href='https://seekingalpha.com/symbol/NVS' title='Novartis AG'>NVS</a> <font color=\"green\">+1.8%</font>)(<a href='https://seekingalpha.com/symbol/BHC' title='Bausch Health Companies Inc.'>BHC</a> <font color=\"green\">+5.1%</font>)(<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a> <font color=\"green\">+6.1%</font>)(<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a> <font color=\"green\">+5.2%</font>)(<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a> <font color=\"green\">+3.7%</font>)(<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a> <font color=\"green\">+4.3%</font>)(<a href='https://seekingalpha.com/symbol/CELG' title='Celgene Corporation'>CELG</a> <font color=\"green\">+6.2%</font>)(<a href='https://seekingalpha.com/symbol/VRTX' title='Vertex Pharmaceuticals Incorporated'>VRTX</a> <font color=\"green\">+5.3%</font>)(<a href='https://seekingalpha.com/symbol/XTLB' title='XTL Biopharmaceuticals Ltd.'>XTLB</a> <font color=\"green\">+10.4%</font>)(<a href='https://seekingalpha.com/symbol/VTL' title='Vital Therapies, Inc.'>VTL</a> <font color=\"green\">+18.4%</font>)(<a href='https://seekingalpha.com/symbol/SNDX' title='Syndax Pharmaceuticals, Inc.'>SNDX</a> <font color=\"green\">+16.9%</font>)(<a href='https://seekingalpha.com/symbol/SPHS' title='Sophiris Bio'>SPHS</a> <font color=\"green\">+24.3%</font>)(<a href='https://seekingalpha.com/symbol/SCYX' title='SCYNEXIS, Inc.'>SCYX</a> <font color=\"green\">+15.2%</font>)(<a href='https://seekingalpha.com/symbol/RETA' title='Reata Pharmaceuticals'>RETA</a> <font color=\"green\">+12.8%</font>)(<a href='https://seekingalpha.com/symbol/PBYI' title='Puma Biotechnology, Inc.'>PBYI</a> <font color=\"green\">+3.2%</font>)(<a href='https://seekingalpha.com/symbol/HSGX' title='Histogenics Corporation'>HSGX</a> <font color=\"green\">+23.9%</font>)(<a href='https://seekingalpha.com/symbol/FLKS' title='Flex Pharma'>FLKS</a> <font color=\"green\">+47.1%</font>)(<a href='https://seekingalpha.com/symbol/DRRX' title='Durect Corporation'>DRRX</a> <font color=\"green\">+26.1%</font>)(<a href='https://seekingalpha.com/symbol/CDTX' title='Cidara Therapeutics'>CDTX</a> <font color=\"green\">+10.4%</font>)(<a href='https://seekingalpha.com/symbol/CTIC' title='CTI BioPharma Corp.'>CTIC</a> <font color=\"green\">+28.8%</font>)(<a href='https://seekingalpha.com/symbol/BPTH' title='Bio-Path Holdings, Inc.'>BPTH</a> <font color=\"green\">+19.6%</font>)(<a href='https://seekingalpha.com/symbol/AKAO' title='Achaogen'>AKAO</a> <font color=\"green\">+44.9%</font>)(<a href='https://seekingalpha.com/symbol/FLGT' title='Fulgent Genetics'>FLGT</a> <font color=\"green\">+19%</font>)(<a href='https://seekingalpha.com/symbol/CRSP' title='CRISPR Therapeutics'>CRSP</a> <font color=\"green\">+10.1%</font>)(<a href='https://seekingalpha.com/symbol/KRYS' title='Krystal Biotech'>KRYS</a> <font color=\"green\">+12.1%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3420766\" data-linked=\"Biotechs lead broad market advance, XBI up 5%\" data-tweet=\"$RHHBY $XBI $XLV - Biotechs lead broad market advance, XBI up 5% https://seekingalpha.com/news/3420766-biotechs-lead-broad-market-advance-xbi-up-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3420766-biotechs-lead-broad-market-advance-xbi-up-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420769\" data-ts=\"1546625302\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420769-stocks-hold-onto-strong-gains-amid-jobs-fed-trade-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stocks hold onto strong gains amid jobs, Fed, trade news</a></h4><ul><li>Stocks continue their strong advance amid a blowout December jobs report, optimism on China-U.S. trade talks, and reassurance from the Fed that it's prepared to shift policy quickly if needed.</li><li>In early afternoon, the S&amp;P is <font color=\"green\">up 3.6%</font>, touching its highest point in more than a week; Nasdaq <font color=\"green\">+4.4%</font> and the Dow<font color=\"green\"> +3.6%</font>.</li><li>By sector, technology (<font color=\"green\">+4.0%</font>) and services (<font color=\"green\">+4.0%</font>) lead the pack. Utilities (<font color=\"green\">+1.4%</font>) and conglomerates (<font color=\"green\">+2.0%</font>) rise the least.</li><li>Notable movers include Microsoft (<font color=\"green\">+5.0%</font>), Alphabet (<font color=\"green\">+4.7%</font>), Facebook (<font color=\"green\">+</font>4.2%), and Amazon (<font color=\"green\">+5.4%</font>). Apple (<font color=\"green\">+3.8%</font>) regains some of the ground it lost on Thursday.</li><li>There are pockets of red in retail, specifically auto parts stores--O'Reilly Automotive (<font color=\"red\">-0.8%</font>), Autozone (<font color=\"red\">-0.6%</font>), and Advance Auto Parts (<font color=\"red\">-1.0%</font>); Macy's (<font color=\"red\">-1.3%</font>) and The Gap (<font color=\"red\">-0.5%</font>) also decline.</li><li>Oil <font color=\"green\">gains 1.7%</font> to $47.91/bbl, and gold<font color=\"red\"> slides 0.8%</font> to $1,284.60/ounce.</li><li>The dollar index edges<font color=\"red\"> down 0.1%</font> to 96.18.</li><li>10-year Treasury falls, pushing yield up almost 12 basis points to 2.67%.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420769\" data-linked=\"Stocks hold onto strong gains amid jobs, Fed, trade news\" data-tweet=\"Stocks hold onto strong gains amid jobs, Fed, trade news https://seekingalpha.com/news/3420769-stocks-hold-onto-strong-gains-amid-jobs-fed-trade-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3420769-stocks-hold-onto-strong-gains-amid-jobs-fed-trade-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420767\" data-ts=\"1546624759\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FCX\" target=\"_blank\">FCX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420767-copper-bounces-china-eases-reserve-requirements-eyes-u-s-trade-talks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Copper bounces as China eases reserve requirements, eyes U.S. trade talks</a></h4><ul><li><a href=\"https://www.reuters.com/article/global-metals/metals-copper-rebounds-as-china-and-u-s-prepare-for-trade-talks-idUSL8N1Z428Y\" target=\"_blank\">Copper prices rally</a> from yesterday\u2019s 18-month low after China cut bank reserve requirements and announced new trade talks with the U.S.; LME copper closed <font color=\"green\">+3.2%</font> at $5,918/metric ton.</li><li>\u201cChina\u2019s easing [of reserve requirements] has managed to turn round the downtrend,\u201d says Societe Generale's Robin Bhar. \u201cBut all this could retrace next week, depending on the trade talks. If the trade dispute escalates, this rally will be short-lived.\u201d</li><li>Bhar expects industrial metals prices to rise 5%-10% in 2019 because any weakness in demand would be offset by tight supply.</li><li>Among major industrial metals stocks: <a href='https://seekingalpha.com/symbol/FCX' title='Freeport-McMoRan Inc.'>FCX</a> <font color=\"green\">+8.3%</font>, <a href='https://seekingalpha.com/symbol/BHP' title='BHP Billiton Limited'>BHP</a> <font color=\"green\">+6.7%</font>, <a href='https://seekingalpha.com/symbol/RIO' title='Rio Tinto plc'>RIO</a> <font color=\"green\">+6.1%</font>, <a href='https://seekingalpha.com/symbol/VALE' title='Vale S.A.'>VALE</a> <font color=\"green\">+9.2%</font>, <a href='https://seekingalpha.com/symbol/TECK' title='Teck Resources Limited'>TECK</a> <font color=\"green\">+6.5%</font>, <a href='https://seekingalpha.com/symbol/AA' title='Alcoa Corporation'>AA</a> <font color=\"green\">+8.2%</font>, <a href='https://seekingalpha.com/symbol/CENX' title='Century Aluminum Company'>CENX</a> <font color=\"green\">+11.5%</font>, <a href='https://seekingalpha.com/symbol/CLF' title='Cleveland-Cliffs, Inc.'>CLF</a> <font color=\"green\">+10.5%</font>, <a href='https://seekingalpha.com/symbol/X' title='United States Steel Corporation'>X</a> <font color=\"green\">+9.3%</font>, <a href='https://seekingalpha.com/symbol/AKS' title='AK Steel Holding Corp'>AKS</a> <font color=\"green\">+12.2%</font>, <a href='https://seekingalpha.com/symbol/MT' title='ArcelorMittal'>MT</a> <font color=\"green\">+8.1%</font>, <a href='https://seekingalpha.com/symbol/ATI' title='Allegheny Technologies Incorporated'>ATI</a> <font color=\"green\">+6.7%</font>, <a href='https://seekingalpha.com/symbol/CSTM' title='Constellium Holdco B.V.'>CSTM</a> <font color=\"green\">+8.5%</font>, <a href='https://seekingalpha.com/symbol/SCCO' title='Southern Copper Corporation'>SCCO</a> <font color=\"green\">+8.2%</font>, <a href='https://seekingalpha.com/symbol/CF' title='CF Industries Holdings, Inc.'>CF</a> <font color=\"green\">+7.9%</font>, <a href='https://seekingalpha.com/symbol/MOS' title='The Mosaic Company'>MOS</a> <font color=\"green\">+6.9%</font>, <a href='https://seekingalpha.com/symbol/NTR' title='Nutrien Ltd.'>NTR</a> <font color=\"green\">+4.3%</font>, <a href='https://seekingalpha.com/symbol/SQM' title='Chemical & Mining Co. of Chile Inc.'>SQM</a> <font color=\"green\">+5%</font>.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/JJCTF' title='iPath DJ-UBS Copper Total Return Sub-Index ETN'>OTCPK:JJCTF</a>, <a href='https://seekingalpha.com/symbol/COPX' title='Global X Copper Miners ETF'>COPX</a>, <a href='https://seekingalpha.com/symbol/DBB' title='Invesco DB Base Metals ETF'>DBB</a>, <a href='https://seekingalpha.com/symbol/CPER' title='United States Copper Index ETF'>CPER</a>, <a href='https://seekingalpha.com/symbol/BOM' title='DB Base Metals Double Short ETN'>BOM</a>, <a href='https://seekingalpha.com/symbol/BDD' title='DB Base Metals Double Long ETN'>BDD</a>, <a href='https://seekingalpha.com/symbol/JJM' title='iPath DJ-UBS Industrial Metals Total Return Sub-Index ETN'>JJM</a>, <a href='https://seekingalpha.com/symbol/BOS' title='DB Base Metals Short ETN'>BOS</a>, <a href='https://seekingalpha.com/symbol/RJZ' title='ELEMENTS Rogers International Commodity Metal ETN'>RJZ</a>, <a href='https://seekingalpha.com/symbol/UBM' title='UBS ETRACS CMCI Industrial Metals Total Return ETN'>UBM</a>,</li></ul><div class=\"tiny-share-widget\" data-id=\"3420767\" data-linked=\"Copper bounces as China eases reserve requirements, eyes U.S. trade talks\" data-tweet=\"$FCX $FCX $BHP - Copper bounces as China eases reserve requirements, eyes U.S. trade talks https://seekingalpha.com/news/3420767-copper-bounces-china-eases-reserve-requirements-eyes-u-s-trade-talks?source=tweet\" data-url=\"https://seekingalpha.com/news/3420767-copper-bounces-china-eases-reserve-requirements-eyes-u-s-trade-talks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420764\" data-ts=\"1546624549\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GNBT\" target=\"_blank\">GNBT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420764-generex-up-26-on-possible-nugenerex-spinout\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Generex up 26% on possible NuGenerex spinout</a></h4><ul><li>Thinly traded nano cap Generex Biotechnology (<a href='https://seekingalpha.com/symbol/GNBT' title='Generex Biotechnology Corp.'>OTCQB:GNBT</a> <font color=\"green\">+25.9%</font>) is up on almost double normal volume, albeit turnover of only 250K shares, following its <a href=\"https://seekingalpha.com/pr/17370587-generex-biotechnology-provides-update-nugenerex-immuno-oncology\" target=\"_blank\">update </a>on developments at subsidiary NuGenerex Immuno-Oncology (formerly Antigen Express).</li><li>A combination trial evaluating Merck's (<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co Inc.'>MRK</a> <font color=\"green\">+2.9%</font>) Keytruda (pembrolizumab) and peptide vaccine AE37 in metastatic triple-negative breast cancer is advancing. Site selection is underway, study drugs are being packaged and the Institutional Review Board is reviewing the protocol.</li><li>Generex has initiated partnering discussions for co-development and collaborative R&amp;D opportunities in I-O and immunotherapies.</li><li>It is also mulling a spinout of NuGenerex Immuno-Oncology after which it will operate independently with its own stock listing. Specifically, the spinout will be executed by issuing one or more dividends of NuGenerex stock to GNBT shareholders. GNBT expects to retain a controlling interest.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420764\" data-linked=\"Generex up 26% on possible NuGenerex spinout\" data-tweet=\"$GNBT $GNBT $MRK - Generex up 26% on possible NuGenerex spinout https://seekingalpha.com/news/3420764-generex-up-26-on-possible-nugenerex-spinout?source=tweet\" data-url=\"https://seekingalpha.com/news/3420764-generex-up-26-on-possible-nugenerex-spinout\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:55 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420763\" data-ts=\"1546624472\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OCN\" target=\"_blank\">OCN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420763-ocwen-leads-financial-gainers-u-s-global-investors-and-maiden-holdings-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ocwen leads financial gainers; U.S. Global Investors and Maiden Holdings among losers</a></h4><ul><li><b>Gainers: </b>Ocwen Financial (NYSE:<a href='https://seekingalpha.com/symbol/OCN' title='Ocwen Financial Corporation'>OCN</a>) <font color=\"green\">+12%</font>. Ladenburg Thalmann Financial Services (NYSEMKT:<a href='https://seekingalpha.com/symbol/LTS' title='Ladenburg Thalmann Financial Services Inc.'>LTS</a>) <font color=\"green\">+10%</font>. Yirendai (NYSE:<a href='https://seekingalpha.com/symbol/YRD' title='Yirendai LTD.'>YRD</a>) <font color=\"green\">+9%</font>. EverQuote (NASDAQ:<a href='https://seekingalpha.com/symbol/EVER' title='EverQuote'>EVER</a>) <font color=\"green\">+9%</font>. Plymouth Industrial REIT (NYSEMKT:<a href='https://seekingalpha.com/symbol/PLYM' title='Plymouth Industrial REIT'>PLYM</a>) <font color=\"green\">+9%</font>.</li><li><b>Losers: </b>Maiden Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/MHLD' title='Maiden Hldgs Ltd'>MHLD</a>) <font color=\"red\">-7%. </font>Wheeler Real Estate Investment Trust (NASDAQ:<a href='https://seekingalpha.com/symbol/WHLR' title='Wheeler Real Estate Investment Trust'>WHLR</a>) <font color=\"red\">-5%</font>. U.S. Global Investors (NASDAQ:<a href='https://seekingalpha.com/symbol/GROW' title='U.S. Global Investors, Inc.'>GROW</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420763\" data-linked=\"Ocwen leads financial gainers; U.S. Global Investors and Maiden Holdings among losers\" data-tweet=\"$OCN $OCN $LTS - Ocwen leads financial gainers; U.S. Global Investors and Maiden Holdings among losers https://seekingalpha.com/news/3420763-ocwen-leads-financial-gainers-u-s-global-investors-and-maiden-holdings-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3420763-ocwen-leads-financial-gainers-u-s-global-investors-and-maiden-holdings-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:54 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420762\" data-ts=\"1546624405\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420762-big-day-for-high-yield\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Big day for high-yield</a></h4><ul><li>Panic selling in stocks one day ago has turned into panic buying today, with the Dow threatening to bust 1K points higher (it's currently <font color=\"green\">up 760 points</font>). On a percentage basis, the Nasdaq is leading with a <font color=\"green\">4.25% advance</font>.</li><li>That's spilling over into the roughed-up high-yield sector, with the iShares High Yield (<a href='https://seekingalpha.com/symbol/HYG' title='iShares iBoxx $ High Yield Corporate Bond ETF'>HYG</a> <font color='green'>+1.6%</font>) and the Invesco Senior Loan ETF (<a href='https://seekingalpha.com/symbol/BKLN' title='Invesco Senior Loan ETF'>BKLN</a> <font color='green'>+1.7%</font>) among those sporting major gains even as benchmark yields shoot higher (the 10-year Treasury is up more than 10 basis points).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3420721-powell-gives-averages-additional-boost\" target=\"_blank\">Powell gives averages additional boost</a> (Jan. 4)</li><li>ETFs: <a href='https://seekingalpha.com/symbol/HYG' title='iShares iBoxx $ High Yield Corporate Bond ETF'>HYG</a>, <a href='https://seekingalpha.com/symbol/JNK' title='SPDR Bloomberg Barclays High Yield Bond ETF'>JNK</a>, <a href='https://seekingalpha.com/symbol/OXLC' title='Oxford Lane Capital'>OXLC</a>, <a href='https://seekingalpha.com/symbol/BKLN' title='Invesco Senior Loan ETF'>BKLN</a>, <a href='https://seekingalpha.com/symbol/ECC' title='Eagle Point Credit Company Inc.'>ECC</a>, <a href='https://seekingalpha.com/symbol/DHY' title='Credit Suisse High Yield Bond Fund'>DHY</a>, <a href='https://seekingalpha.com/symbol/HIX' title='Western Asset High Income Fund II'>HIX</a>, <a href='https://seekingalpha.com/symbol/EAD' title='Wells Fargo Advantage Income Opportunities Fund'>EAD</a>, <a href='https://seekingalpha.com/symbol/PHT' title='Pioneer High Income Trust'>PHT</a>, <a href='https://seekingalpha.com/symbol/HYT' title='BlackRock Corporate High Yield Fund, Inc'>HYT</a>, <a href='https://seekingalpha.com/symbol/HYLD' title='Peritus Hgh Yld Shs'>HYLD</a>, <a href='https://seekingalpha.com/symbol/JQC' title='Nuveen Credit Strategies Income Fund'>JQC</a>, <a href='https://seekingalpha.com/symbol/PPR' title='Voya Prime Rate Trust'>PPR</a>, <a href='https://seekingalpha.com/symbol/ACP' title='Aberdeen Income Credit Strategies Fund'>ACP</a>, <a href='https://seekingalpha.com/symbol/ANGL' title='VanEck Vectors Fallen Angel High Yield Bond ETF'>ANGL</a>, <a href='https://seekingalpha.com/symbol/CIK' title='Credit Suisse Asset Management Income Fund'>CIK</a>, <a href='https://seekingalpha.com/symbol/EFR' title='Eaton Vance Senior Floating-Rate Fund'>EFR</a>, <a href='https://seekingalpha.com/symbol/BGB' title='Blackstone/GSO Strategic Credit Fund'>BGB</a>, <a href='https://seekingalpha.com/symbol/MCI' title='Barings Corporate Investors'>MCI</a>, <a href='https://seekingalpha.com/symbol/DSU' title='Blackrock Debt Strategies Fund'>DSU</a>, <a href='https://seekingalpha.com/symbol/VVR' title='Invesco Senior Income Trust'>VVR</a>, <a href='https://seekingalpha.com/symbol/SJB' title='ProShares Short High Yield ETF'>SJB</a>, <a href='https://seekingalpha.com/symbol/KIO' title='KKR Income Opportunities Fund'>KIO</a>, <a href='https://seekingalpha.com/symbol/NSL' title='Nuveen Senior Income Fund'>NSL</a>, <a href='https://seekingalpha.com/symbol/BGX' title='Blackstone/GSO Long-Short Credit Income Fund'>BGX</a>, <a href='https://seekingalpha.com/symbol/PHD' title='Pioneer Floating Rate Trust'>PHD</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3420762\" data-linked=\"Big day for high-yield\" data-tweet=\"$HYG $BKLN $JNK - Big day for high-yield https://seekingalpha.com/news/3420762-big-day-for-high-yield?source=tweet\" data-url=\"https://seekingalpha.com/news/3420762-big-day-for-high-yield\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>60&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420760\" data-ts=\"1546624127\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AKAO\" target=\"_blank\">AKAO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420760-microcaps-mostly-among-midday-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Microcaps mostly among midday movers</a></h4><ul><li><strong>Gainers: </strong>Achaogen (NASDAQ:<a href='https://seekingalpha.com/symbol/AKAO' title='Achaogen'>AKAO</a>) <font color=\"green\">+34%</font>. AAC Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/AAC' title='AAC Holdings, Inc.'>AAC</a>) <font color=\"green\">+32%</font>. Titan Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/TMDI' title='Titan Medical Inc.'>TMDI</a>) <font color=\"green\">+31%</font>. American Midstream Partners (NYSE:<a href='https://seekingalpha.com/symbol/AMID' title='American Midstream Partners, LP'>AMID</a>) <font color=\"green\">+25%</font>. PHI (NASDAQ:<a href='https://seekingalpha.com/symbol/PHII' title='PHI, Inc.'>PHII</a>) <font color=\"green\">+23%</font>. Sienna Biopharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SNNA' title='Sienna Biopharmaceuticals'>SNNA</a>) <font color=\"green\">+22%</font>. Epizyme (NASDAQ:<a href='https://seekingalpha.com/symbol/EPZM' title='Epizyme'>EPZM</a>) <font color=\"green\">+19%</font>. EyePoint Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/EYPT' title='EyePoint Pharmaceuticals, Inc.'>EYPT</a>) <font color=\"green\">+19%</font>. CHF Solutions (NASDAQ:<a href='https://seekingalpha.com/symbol/CHFS' title='CHF Solutions, Inc.'>CHFS</a>) <font color=\"green\">+17%</font>. Miragen Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/MGEN' title='Miragen Therapeutics, Inc.'>MGEN</a>) <font color=\"green\">+17%</font>.</li> <li><strong>Losers:</strong> Arcus Biosciences (NYSE:<a href='https://seekingalpha.com/symbol/RCUS' title='Arcus Biosciences'>RCUS</a>) <font color=\"red\">-15%</font>. Reebonz Holding (<a href='https://seekingalpha.com/symbol/RBZ' title='Reebonz Holding Ltd. Class A'>RBZ</a>) <font color=\"red\">-16%</font>. Boxlight Corporation (NASDAQ:<a href='https://seekingalpha.com/symbol/BOXL' title='Boxlight'>BOXL</a>) <font color=\"red\">-14%</font>. Avadel Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/AVDL' title='Avadel Pharmaceuticals plc'>AVDL</a>) <font color=\"red\">-10%</font>. Regional Health Properties (NYSEMKT:<a href='https://seekingalpha.com/symbol/RHE' title='Regional Health Properties, Inc.'>RHE</a>) <font color=\"red\">-8%</font>. Vaxart (NASDAQ:<a href='https://seekingalpha.com/symbol/VXRT' title='Vaxart, Inc.'>VXRT</a>) <font color=\"red\">-8%</font>. Maiden Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/MHLD' title='Maiden Hldgs Ltd'>MHLD</a>) <font color=\"red\">-8%</font>. Esperion Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ESPR' title='Esperion Therapeutics'>ESPR</a>) <font color=\"red\">-7%</font>. LogicBio Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/LOGC' title='LogicBio'>LOGC</a>) <font color=\"red\">-7%</font>. PLx Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/PLXP' title='PLx Pharma'>PLXP</a>) <font color=\"red\">-7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3420760\" data-linked=\"Microcaps mostly among midday movers\" data-tweet=\"$AKAO $AKAO $AAC - Microcaps mostly among midday movers https://seekingalpha.com/news/3420760-microcaps-mostly-among-midday-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3420760-microcaps-mostly-among-midday-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420755\" data-ts=\"1546622639\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LITE\" target=\"_blank\">LITE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420755-lumentumplus-6_4-analysts-see-apple-cut-already-baked-in\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lumentum +6.4% as analysts see Apple cut already baked in</a></h4><ul>   <li>Lumentum (NASDAQ:<a href='https://seekingalpha.com/symbol/LITE' title='Lumentum Holdings Inc.'>LITE</a>) is rebounding from a slide spurred as part of <a href=\"https://seekingalpha.com/news/3420163-suppliers-drop-apples-warning\" target=\"_blank\">Apple's revenue warnings</a> this week, <font color=\"green\">up 6.4%</font> today with analysts largely sticking up for the stock and suggesting an overreaction.</li>    <li>Shares <font color=\"red\">fell 8.4%</font> yesterday amid a number of peers declining on the update.</li>    <li>But a heavy rebasing in November from its own <a href=\"https://seekingalpha.com/news/3408439-lumentum-drops-q2-guide-shipment-cut\" target=\"_blank\">guidance cut</a> -- credited to news that Lumentum likely got from Apple -- means that Apple's update is already reflected in Lumentum's share price, a few analysts are saying.</li>    <li>Apple's announcement likely means an impact of 9-10M units, while the November reduction came out to about 15-120M units.</li>    <li>D.A. Davidson is still extremely bullish, reiterating a Buy rating with an $89 price target, implying 114% upside from today's price. Adding Oclaro will help Lumentum become far less dependent on iPhone unit sales, the firm says.</li>    <li>Northland is reiterating an Outperform with a $60 price target. Meanwhile, Needham is trimming forecasts a bit and cutting its target to $65 from $75, but sticking with a Strong Buy on the stock.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3420755\" data-linked=\"Lumentum +6.4% as analysts see Apple cut already baked in\" data-tweet=\"$LITE - Lumentum +6.4% as analysts see Apple cut already baked in https://seekingalpha.com/news/3420755-lumentumplus-6_4-analysts-see-apple-cut-already-baked-in?source=tweet\" data-url=\"https://seekingalpha.com/news/3420755-lumentumplus-6_4-analysts-see-apple-cut-already-baked-in\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420753\" data-ts=\"1546622368\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBR\" target=\"_blank\">PBR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420753-new-petrobras-chief-says-no-to-subsidies-government-intervention\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New Petrobras chief says no to subsidies, government intervention</a></h4><ul><li>Roberto Castello Branco, who was <a href=\"https://www.wsj.com/articles/petrobrass-new-ceo-promises-to-continue-asset-sales-cutting-debt-and-reducing-costs-11546545777\" target=\"_blank\">sworn in yesterday</a> as the new CEO at Petrobras (<a href='https://seekingalpha.com/symbol/PBR' title='Petrobras - Petroleo Brasileiro S.A.'>PBR</a> <font color='green'>+2.8%</font>), tells Bloomberg he is \"<a href=\"https://www.bloomberg.com/news/articles/2019-01-03/new-petrobras-ceo-rejects-subsidies-and-government-intervention\" target=\"_blank\">revolted</a>\" by the company's moral and financial  crises of recent years, and vows to  raise oil production and reduce the huge debt load.</li><li>Criticizing the history of government interference in the company, Castello Branco says \"fuel prices should be in line with international ones, with a sound 'no' to subsidies or to attempts at having a monopoly... We are pro-market economists. We like  competition.\"</li><li>The new CEO also plans to continue PBR\u2019s program of selling non-core assets and use the proceeds to cut debt and invest in promising projects.</li><li>But the extent to which Castello Branco will be able to put his ideas into practice is in doubt: Various courts in Brazil have suspended major PBR asset sales in recent months, the company is locked in a dispute with the government over the so-called transfer-of-rights area, and Brazil's people have consistently opposed selling off public firms in part or in whole.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420753\" data-linked=\"New Petrobras chief says no to subsidies, government intervention\" data-tweet=\"$PBR - New Petrobras chief says no to subsidies, government intervention https://seekingalpha.com/news/3420753-new-petrobras-chief-says-no-to-subsidies-government-intervention?source=tweet\" data-url=\"https://seekingalpha.com/news/3420753-new-petrobras-chief-says-no-to-subsidies-government-intervention\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420746\" data-ts=\"1546621242\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SORL\" target=\"_blank\">SORL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420746-mattel-and-orchids-paper-products-among-consumer-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mattel and Orchids Paper Products among consumer gainers</a></h4><ul><li><b>Gainers: </b>SORL Auto Parts (NASDAQ:<a href='https://seekingalpha.com/symbol/SORL' title='SORL Auto Parts, Inc.'>SORL</a>) <font color=\"green\">+12%</font>. China XD Plastics (NASDAQ:<a href='https://seekingalpha.com/symbol/CXDC' title='China XD Plastics Company Limited'>CXDC</a>) <font color=\"green\">+10%</font>. Mattel (NASDAQ:<a href='https://seekingalpha.com/symbol/MAT' title='Mattel, Inc.'>MAT</a>) <font color=\"green\">+9%</font>. Orchids Paper Products (NYSEMKT:<a href='https://seekingalpha.com/symbol/TIS' title='Orchids Paper Products Company'>TIS</a>) <font color=\"green\">+8%</font>. Electrameccanica Vehicles (NASDAQ:<a href='https://seekingalpha.com/symbol/SOLO' title='Electrameccanica Vehicles Corp. Ltd.'>SOLO</a>) <font color=\"green\">+8%</font>.</li><li><b>Losers: </b>None</li></ul><div class=\"tiny-share-widget\" data-id=\"3420746\" data-linked=\"Mattel and Orchids Paper Products among consumer gainers\" data-tweet=\"$SORL $SORL $CXDC - Mattel and Orchids Paper Products among consumer gainers https://seekingalpha.com/news/3420746-mattel-and-orchids-paper-products-among-consumer-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3420746-mattel-and-orchids-paper-products-among-consumer-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420743\" data-ts=\"1546620864\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KALV\" target=\"_blank\">KALV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420743-kalvista-up-2-on-pipeline-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KalVista up 2% on pipeline update</a></h4><ul><li>Thinly traded micro cap KalVista Pharmaceuticals (<a href='https://seekingalpha.com/symbol/KALV' title='KalVista Pharmaceticals, Inc.'>KALV</a> <font color=\"green\">+1.7%</font>) is up on light volume following its <a href=\"https://www.businesswire.com/news/home/20190104005232/en/KalVista-Pharmaceuticals-Development-Update-2019-Clinical-Plans\" target=\"_blank\">pipeline update </a>for investors. Key points:</li><li><strong>KVD900</strong>: Data from its expanded Phase 2 study in hereditary angioedema should be available in Q4. On-demand dosing in 50 patients in Europe to start after regulatory sign-off.</li><li><strong>KVD824</strong>: Dosing in Phase 1 study to commence soon. Further update will be made mid-year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420743\" data-linked=\"KalVista up 2% on pipeline update\" data-tweet=\"$KALV - KalVista up 2% on pipeline update https://seekingalpha.com/news/3420743-kalvista-up-2-on-pipeline-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3420743-kalvista-up-2-on-pipeline-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:54 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420737\" data-ts=\"1546619821\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNTA\" target=\"_blank\">MNTA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420737-momenta-pharma-slips-4-on-jpmorgan-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Momenta Pharma slips 4% on JPMorgan downgrade</a></h4><ul><li>Momenta Pharmaceuticals (<a href='https://seekingalpha.com/symbol/MNTA' title='Momenta Pharmaceuticals, Inc.'>MNTA</a> <font color=\"red\">-3.6%</font>) is down on lower-than-average volume following a downgrade to Neutral at JPMorgan. Analyst Eric Joseph trimmed his fair value target almost in half to $12 (16% upside) citing the long timelines for key assets.</li><li>Phase 2 data on M281 in myasthenia gravis, for example, won't be available until 2020.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420737\" data-linked=\"Momenta Pharma slips 4% on JPMorgan downgrade\" data-tweet=\"$MNTA - Momenta Pharma slips 4% on JPMorgan downgrade https://seekingalpha.com/news/3420737-momenta-pharma-slips-4-on-jpmorgan-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3420737-momenta-pharma-slips-4-on-jpmorgan-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420738\" data-ts=\"1546619811\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LNG\" target=\"_blank\">LNG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420738-cheniere-approved-ferc-to-start-production-corpus-christi-train-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cheniere approved by FERC to start production at Corpus Christi Train 2</a></h4><ul><li>Cheniere Energy (<a href='https://seekingalpha.com/symbol/LNG' title='Cheniere Energy, Inc'>LNG</a> <font color=\"green\">+2.2%</font>) wins permission from the Federal Energy Regulatory Commission to <a href=\"https://www.chron.com/business/energy/article/Feds-give-Cheniere-green-light-to-start-13505857.php\" target=\"_blank\">begin the startup process</a> for the second production unit at its Corpus Christi LNG facility.</li><li>The introduction of natural gas into the unit allows Cheniere to begin  testing and the commissioning process.</li><li>The first production unit at Cheniere's Port of Corpus Christi facility  was brought into service in November with full commercial  service expected during Q1, while Train 2 is expected to reach full  service during H2.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420738\" data-linked=\"Cheniere approved by FERC to start production at Corpus Christi Train 2\" data-tweet=\"$LNG - Cheniere approved by FERC to start production at Corpus Christi Train 2 https://seekingalpha.com/news/3420738-cheniere-approved-ferc-to-start-production-corpus-christi-train-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3420738-cheniere-approved-ferc-to-start-production-corpus-christi-train-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420736\" data-ts=\"1546619334\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IRWD\" target=\"_blank\">IRWD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420736-ironwood-names-astrazeneca-exec-ceo-shares-up-8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ironwood names AstraZeneca exec as CEO; shares up 8%</a></h4><ul><li>Ironwood Pharmaceuticals (<a href='https://seekingalpha.com/symbol/IRWD' title='Ironwood Pharmaceuticals, Inc.'>IRWD</a> <font color=\"green\">+7.5%</font>) is up on below-average volume following the <a href=\"https://www.wsj.com/articles/ironwood-pharmaceuticals-picks-astrazeneca-executive-to-be-next-ceo-11546617660\" target=\"_blank\">news </a>that it has hired former AstraZeneca (<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a> <font color=\"green\">+2.2%</font>) strategy chief Mark Mallon as its new CEO.</li><li>He will initially serve as an advisor to the board until the company spins out a new business focused on drugs for rare diseases. At this point, he will take the reins from current CEO Peter Hecht.</li><li><strong>Update</strong>: In a <a href=\"https://seekingalpha.com/pr/17370746-ironwood-pharmaceuticals-announces-chief-executive-officers-lead-ironwood-cyclerion-effective\" target=\"_blank\">statement</a>, Ironwood confirmed the move, adding that the spinout should be completed in H1.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420736\" data-linked=\"Ironwood names AstraZeneca exec as CEO; shares up 8%\" data-tweet=\"$IRWD $IRWD $AZN - Ironwood names AstraZeneca exec as CEO; shares up 8% https://seekingalpha.com/news/3420736-ironwood-names-astrazeneca-exec-ceo-shares-up-8?source=tweet\" data-url=\"https://seekingalpha.com/news/3420736-ironwood-names-astrazeneca-exec-ceo-shares-up-8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420732\" data-ts=\"1546618451\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TMDI\" target=\"_blank\">TMDI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420732-titan-medical-builds-on-sport-surgical-system-stoked-up-move-shares-ahead-28\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Titan Medical builds on Sport Surgical System-stoked up move; shares ahead 28%</a></h4><ul><li>Thinly traded nano cap Titan Medical (<a href='https://seekingalpha.com/symbol/TMDI' title='Titan Medical Inc.'>TMDI</a> <font color=\"green\">+28.2%</font>) is up on more than double normal volume, albeit on turnover of only 162K shares. The stock has rallied almost <font color=\"green\">60%</font> since touching $1.07 on December 27, 2018.</li><li>On Wednesday, it <a href=\"https://seekingalpha.com/pr/17368418-titan-medical-affirms-timeline-u-s-eu-regulatory-submissions-year-end-2019-sport-surgical\" target=\"_blank\">announced </a>that it expects to file a 501(k) application in the U.S. by year-end seeking clearance for its Sport Surgical System. It plans to file for CE Mark certification at the same time. Commercialization should start in 2020.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420732\" data-linked=\"Titan Medical builds on Sport Surgical System-stoked up move; shares ahead 28%\" data-tweet=\"$TMDI - Titan Medical builds on Sport Surgical System-stoked up move; shares ahead 28% https://seekingalpha.com/news/3420732-titan-medical-builds-on-sport-surgical-system-stoked-up-move-shares-ahead-28?source=tweet\" data-url=\"https://seekingalpha.com/news/3420732-titan-medical-builds-on-sport-surgical-system-stoked-up-move-shares-ahead-28\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:14 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420731\" data-ts=\"1546618033\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BAYRY\" target=\"_blank\">BAYRY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420731-bayerplus-6-after-judge-limits-evidence-in-trial-over-roundup-cancer-claims\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bayer +6% after judge limits evidence in trial over Roundup cancer claims</a></h4><ul><li>Bayer (<a href='https://seekingalpha.com/symbol/BAYRY' title='Bayer A.G. ADR'>OTCPK:BAYRY</a> <font color='green'>+5.8%</font>) jumps after a U.S. judge overseeing lawsuits alleging its recently acquired Roundup weedkiller causes cancer issues a ruling that could <a href=\"https://www.reuters.com/article/us-bayer-glyphosate-lawsuit/u-s-judge-limits-evidence-in-trial-over-roundup-cancer-claims-idUSKCN1OY03N\" target=\"_blank\">severely restrict evidence</a> that the plaintiffs consider crucial to their cases.</li><li>The judge yesterday granted Bayer unit Monsanto\u2019s request to split an upcoming trial into two phases, an order that initially bars plaintiff lawyers from introducing evidence that the company allegedly attempted to influence regulators and manipulate public opinion.</li><li>The order applies to the case scheduled to go to trial on Feb. 25 and two other bellwether trials which will help determine the range of damages and define settlement options for the rest of the 620 Roundup cases before the judge.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420731\" data-linked=\"Bayer +6% after judge limits evidence in trial over Roundup cancer claims\" data-tweet=\"$BAYRY - Bayer +6% after judge limits evidence in trial over Roundup cancer claims https://seekingalpha.com/news/3420731-bayerplus-6-after-judge-limits-evidence-in-trial-over-roundup-cancer-claims?source=tweet\" data-url=\"https://seekingalpha.com/news/3420731-bayerplus-6-after-judge-limits-evidence-in-trial-over-roundup-cancer-claims\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420730\" data-ts=\"1546617854\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KOOL\" target=\"_blank\">KOOL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420730-cesca-therapeutics-all-in-thermogenesis-forms-new-subsidiary-shares-up-25\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cesca Therapeutics all in with ThermoGenesis, forms new subsidiary; shares up 25%</a></h4><ul><li>Thinly traded nano cap Cesca Therapeutics (<a href='https://seekingalpha.com/symbol/KOOL' title='Cesca Therapeutics Inc'>KOOL</a> <font color=\"green\">+24.7%</font>) is up on average volume on the heels of its <a href=\"https://seekingalpha.com/pr/17370558-cesca-therapeutics-acquires-remaining-ownership-stake-thermogenesis-forms-new-thermogenesis\" target=\"_blank\">announcement </a>that it has acquired the remaining 20% of subsidiary Thermogenesis that it did not own from Bay City Capital &#40;BCC&#41;.</li><li>BCC will have own a 20% stake in a newly created subsidiary of Thermogenesis called CARTXpress Bio that will focus on its CAR-TXpress cellular processing platform.</li><li>Thermogenesis will focus on the development and commercialization of automated medical devices and technologies for cell therapies, including stem cell banking, point-of-care applications and large-scale manufacturing of immunotherapies like CAR-Ts, leveraging its AutoXpress, POCXpress and CAR-TXpress platforms.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420730\" data-linked=\"Cesca Therapeutics all in with ThermoGenesis, forms new subsidiary; shares up 25%\" data-tweet=\"$KOOL $THMO - Cesca Therapeutics all in with ThermoGenesis, forms new subsidiary; shares up 25% https://seekingalpha.com/news/3420730-cesca-therapeutics-all-in-thermogenesis-forms-new-subsidiary-shares-up-25?source=tweet\" data-url=\"https://seekingalpha.com/news/3420730-cesca-therapeutics-all-in-thermogenesis-forms-new-subsidiary-shares-up-25\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:04 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420729\" data-ts=\"1546617765\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TMDI\" target=\"_blank\">TMDI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420729-epizyme-and-selecta-biosciences-among-healthcare-gainers-avadel-pharmaceuticals-and-cocrystal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Epizyme and Selecta Biosciences among healthcare gainers; Avadel Pharmaceuticals and Cocrystal Pharma among losers</a></h4><ul><li><b>Gainers: </b>Titan Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/TMDI' title='Titan Medical Inc.'>TMDI</a>) <font color=\"green\">+28%</font>. Selecta Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/SELB' title='Selecta Biosciences'>SELB</a>) <font color=\"green\">+19%</font>. Genprex (NASDAQ:<a href='https://seekingalpha.com/symbol/GNPX' title='Genprex, Inc'>GNPX</a>) <font color=\"green\">+17%</font>. Epizyme (NASDAQ:<a href='https://seekingalpha.com/symbol/EPZM' title='Epizyme'>EPZM</a>) <font color=\"green\">+17%</font>. AAC Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/AAC' title='AAC Holdings, Inc.'>AAC</a>) <font color=\"green\">+16%</font>.</li><li><b>Losers: </b>Arcus Biosciences (NYSE:<a href='https://seekingalpha.com/symbol/RCUS' title='Arcus Biosciences'>RCUS</a>) <font color=\"red\">-14%</font>. LogicBio Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/LOGC' title='LogicBio'>LOGC</a>) <font color=\"red\">-10%</font>. Regional Health Properties (NYSEMKT:<a href='https://seekingalpha.com/symbol/RHE' title='Regional Health Properties, Inc.'>RHE</a>) <font color=\"red\">-9%</font>. Avadel Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/AVDL' title='Avadel Pharmaceuticals plc'>AVDL</a>) <font color=\"red\">-9%</font>. Cocrystal Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/COCP' title='Cocrystal Pharma, Inc.'>COCP</a>) <font color=\"red\">-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420729\" data-linked=\"Epizyme and Selecta Biosciences among healthcare gainers; Avadel Pharmaceuticals and Cocrystal Pharma among losers\" data-tweet=\"$TMDI $TMDI $SELB - Epizyme and Selecta Biosciences among healthcare gainers; Avadel Pharmaceuticals and Cocrystal Pharma among losers https://seekingalpha.com/news/3420729-epizyme-and-selecta-biosciences-among-healthcare-gainers-avadel-pharmaceuticals-and-cocrystal?source=tweet\" data-url=\"https://seekingalpha.com/news/3420729-epizyme-and-selecta-biosciences-among-healthcare-gainers-avadel-pharmaceuticals-and-cocrystal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:02 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420728\" data-ts=\"1546617713\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420728-gasoline-distillates-inventory-unexpectedly-rise\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gasoline &amp; Distillates inventory unexpectedly rise</a></h4><ul>     <li><a href=\"http://ir.eia.gov/wpsr/wpsrsummary.pdf\" target=\"_blank\">EIA Petroleum Inventories</a>: Crude <strong>0.0M </strong>barrels vs. -3.1M consensus, 0.0M last week.</li> <li>Gasoline<strong> +6.9M</strong> barrels vs. +2.0M consensus, +3.0M last week.</li> <li>Distillates <strong>+9.5M </strong>barrels vs. +1.6M consensus, 0.0M last week.</li> <li>Futures <font color=\"green\">+3.95%</font> to $48.95.</li> <li>ETFs: <a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>, <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P Crude Oil Total Return Index ETN'>OIL</a>, <a href='https://seekingalpha.com/symbol/UCO' title='ProShares Ultra Bloomberg Crude Oil ETF'>UCO</a>, <a href='https://seekingalpha.com/symbol/SCO' title='ProShares UltraShort Bloomberg Crude Oil ETF'>SCO</a>, <a href='https://seekingalpha.com/symbol/BNO' title='The United States Brent Oil ETF, LP'>BNO</a>, <a href='https://seekingalpha.com/symbol/DTO' title='DB Crude Oil Double Short ETN'>DTO</a>, <a href='https://seekingalpha.com/symbol/DBO' title='Invesco DB Oil ETF'>DBO</a>, <a href='https://seekingalpha.com/symbol/USL' title='The United States 12 Month Oil ETF, LP'>USL</a>, <a href='https://seekingalpha.com/symbol/DNO' title='The United States Short Oil ETF, LP'>DNO</a>, <a href='https://seekingalpha.com/symbol/SZO' title='DB Crude Oil Short ETN'>SZO</a>, <a href='https://seekingalpha.com/symbol/OLO' title='DB Crude Oil Long ETN'>OLO</a>, <a href='https://seekingalpha.com/symbol/OLEM' title='iPath Pure Beta Crude Oil ETN'>OLEM</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3420728\" data-linked=\"Gasoline &amp; Distillates inventory unexpectedly rise\" data-tweet=\"$USO $OIL $UCO - Gasoline &amp; Distillates inventory unexpectedly rise https://seekingalpha.com/news/3420728-gasoline-distillates-inventory-unexpectedly-rise?source=tweet\" data-url=\"https://seekingalpha.com/news/3420728-gasoline-distillates-inventory-unexpectedly-rise\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>44&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420726\" data-ts=\"1546617520\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COTY\" target=\"_blank\">COTY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420726-cotyplus-5-after-shaking-off-bear-call\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Coty +5% after shaking off bear call</a></h4><ul> <li>JPMorgan lifts Coty (<a href='https://seekingalpha.com/symbol/COTY' title='Coty Inc.'>COTY</a> <font color='green'>+5%</font>) to a Neutral rating after having the cosmetics seller set at Underweight.</li> <li>A sum-of-the-parts evaluation by JPMorgan points to a <a href=\"https://www.barrons.com/articles/gamestop-stock-skyrockets-honeywell-gains-and-3-more-friday-morning-movers-51546611201?mod=hp_LATEST\" target=\"_blank\">$7 fair value</a> on Coty and on top of that the firm thinks Coty might divest its struggling consumer beauty division.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3420726\" data-linked=\"Coty +5% after shaking off bear call\" data-tweet=\"$COTY - Coty +5% after shaking off bear call https://seekingalpha.com/news/3420726-cotyplus-5-after-shaking-off-bear-call?source=tweet\" data-url=\"https://seekingalpha.com/news/3420726-cotyplus-5-after-shaking-off-bear-call\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420725\" data-ts=\"1546617472\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VG\" target=\"_blank\">VG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420725-vonageplus-6_9-stephens-sees-mispriced-stock-after-decline\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vonage +6.9% as Stephens sees &#39;mispriced&#39; stock after decline</a></h4><ul>   <li>Vonage (NYSE:<a href='https://seekingalpha.com/symbol/VG' title='Vonage Holdings Corp.'>VG</a>) is <font color=\"green\">up 6.9%</font> after a <a href=\"https://seekingalpha.com/news/3420541-vonage-8x8-rise-bullish-note-stephens\" target=\"_blank\">Stephens update</a> on communications services calls it a \"mispriced\" opportunity.</li>    <li>A decline over the past four months showed the stock was \"caught in a perfect storm of unfavorable earnings headlines, macro worries of looming recession and year-end repositioning,\" the firm said -- all \"transitory\" items that got reflected in the stock price. (h/t Bloomberg)</li>    <li>Stephens is overweight on Vonage and similarly bullish on 8x8 (<a href=\"http://seekingalpha.com/symbol/EGHT\" target=\"_blank\">EGHT</a> <font color=\"green\">+6.6%</font>); meanwhile, it's Equal Weight on LogMeIn (<a href=\"http://seekingalpha.com/symbol/LOGM\" target=\"_blank\">LOGM</a> <font color=\"green\">+2.9%</font>) and Twilio (<a href=\"http://seekingalpha.com/symbol/TWLO\" target=\"_blank\">TWLO</a> <font color=\"green\">+7.5%</font>).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3420725\" data-linked=\"Vonage +6.9% as Stephens sees &#39;mispriced&#39; stock after decline\" data-tweet=\"$VG $VG $EGHT - Vonage +6.9% as Stephens sees &#39;mispriced&#39; stock after decline https://seekingalpha.com/news/3420725-vonageplus-6_9-stephens-sees-mispriced-stock-after-decline?source=tweet\" data-url=\"https://seekingalpha.com/news/3420725-vonageplus-6_9-stephens-sees-mispriced-stock-after-decline\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420722\" data-ts=\"1546617220\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CPRX\" target=\"_blank\">CPRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420722-catalyst-pharma-up-7-on-firdapse-data-in-myasthenia-gravis\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Catalyst Pharma up 7% on Firdapse data in myasthenia gravis</a></h4><ul><li>Catalyst Pharmaceuticals (<a href='https://seekingalpha.com/symbol/CPRX' title='Catalyst Pharmaceuticals, Inc.'>CPRX</a> <font color=\"green\">+6.5%</font>) is up on below-average volume on the heels of the publication of <a href=\"https://seekingalpha.com/pr/17370527-catalyst-pharmaceuticals-announces-publication-clinical-data-investigator-sponsored-phase-iib\" target=\"_blank\">Phase 2b data</a> on Firdapse (amifampridine phosphate) in patients with MuSK antibody-positive myasthenia gravis (MuSK-MG).</li><li>The results, <a href=\"https://journals.sagepub.com/doi/full/10.1177/2050312118819013\" target=\"_blank\">published online</a> in <em>SAGE Open Medicine</em>, statistically significant improvements in two scales assessing patients' ability to perform daily living activities, the co-primary endpoints.</li><li>A <a href=\"https://clinicaltrials.gov/ct2/show/NCT03304054?lead=catalyst+pharmaceuticals&amp;phase=2&amp;rank=2\" target=\"_blank\">Phase 3 trial</a> in MuSK-MG, a more severe form of MG, is in process.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420722\" data-linked=\"Catalyst Pharma up 7% on Firdapse data in myasthenia gravis\" data-tweet=\"$CPRX - Catalyst Pharma up 7% on Firdapse data in myasthenia gravis https://seekingalpha.com/news/3420722-catalyst-pharma-up-7-on-firdapse-data-in-myasthenia-gravis?source=tweet\" data-url=\"https://seekingalpha.com/news/3420722-catalyst-pharma-up-7-on-firdapse-data-in-myasthenia-gravis\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420721\" data-ts=\"1546617091\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420721-powell-gives-averages-additional-boost\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Powell gives averages additional boost</a></h4><ul><li>Speaking at the American Economic Association, Fed Chair Jay Powell may <a href=\"https://seekingalpha.com/news/3420713-u-s-economy-track-sustain-good-momentum-year-powell-says\" target=\"_blank\">have just officially thrown</a> in the towel on this rate hike cycle, saying the central bank is \"prepared to adjust policy quickly and flexibly.\"</li><li>And it's not just a possible end or pause to rate hikes, but the Fed boss also says balance sheet \"normalization\" is up for adjustment.</li><li>The averages have added to gains, with the Nasdaq now <font color=\"green\">up 3.2%</font> and the S&amp;P 500 <font color=\"green\">2.5%</font>.</li><li>The 10-year Treasury yield is now higher by a whopping 10 basis points to 2.656%.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420721\" data-linked=\"Powell gives averages additional boost\" data-tweet=\"Powell gives averages additional boost https://seekingalpha.com/news/3420721-powell-gives-averages-additional-boost?source=tweet\" data-url=\"https://seekingalpha.com/news/3420721-powell-gives-averages-additional-boost\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>131&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420717\" data-ts=\"1546616329\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATRA\" target=\"_blank\">ATRA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420717-atara-bio-up-9-after-yesterdays-ceo-departure-stoked-selloff\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Atara Bio up 9% after yesterday&#39;s CEO departure-stoked selloff</a></h4><ul><li>Atara Biotherapeutics (<a href='https://seekingalpha.com/symbol/ATRA' title='Atara Biotherapeutics'>ATRA</a> <font color=\"green\">+8.5%</font>) is up on average volume in early trade as buying recovers after yesterday's <font color=\"red\">19%</font> plummet in reaction to the planned <a href=\"https://seekingalpha.com/pr/17369259-atara-biotherapeutics-announces-planned-chief-executive-officer-transition\" target=\"_blank\">departure </a>of CEO Isaac Ciechanover, M.D.</li><li>Cheerleader Canaccord Genuity (BUY/$70) is downplaying the situation saying Dr. Ciechanover's decision was personal and unrelated to the upcoming release of Phase 3 data on tab-cel.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420717\" data-linked=\"Atara Bio up 9% after yesterday&#39;s CEO departure-stoked selloff\" data-tweet=\"$ATRA - Atara Bio up 9% after yesterday&#39;s CEO departure-stoked selloff https://seekingalpha.com/news/3420717-atara-bio-up-9-after-yesterdays-ceo-departure-stoked-selloff?source=tweet\" data-url=\"https://seekingalpha.com/news/3420717-atara-bio-up-9-after-yesterdays-ceo-departure-stoked-selloff\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:38 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420718\" data-ts=\"1546616324\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BKS\" target=\"_blank\">BKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420718-barnes-nobleplus-5-amid-gamestop-buzz\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barnes &amp; Noble +5% amid GameStop buzz</a></h4><ul> <li>Shares of Barnes &amp; Noble (NYSE:<a href='https://seekingalpha.com/symbol/BKS' title='Barnes & Noble Inc'>BKS</a>) are <font color=\"green\">4.55% higher</font> in early trading on a move that could be related to some separate GameStop buyout buzz.</li><li>It wouldn't be the first time that both GameStop and B&amp;N have moved together on investor hopes one or the other would be acquired.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3420714-gamestop-plus-12-percent-buyout-buzz\" target=\"_blank\">GameStop +12% on buyout buzz</a> (Jan. 4)</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3420718\" data-linked=\"Barnes &amp; Noble +5% amid GameStop buzz\" data-tweet=\"$BKS - Barnes &amp; Noble +5% amid GameStop buzz https://seekingalpha.com/news/3420718-barnes-nobleplus-5-amid-gamestop-buzz?source=tweet\" data-url=\"https://seekingalpha.com/news/3420718-barnes-nobleplus-5-amid-gamestop-buzz\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420714\" data-ts=\"1546616015\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GME\" target=\"_blank\">GME</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420714-gamestopplus-12-on-buyout-buzz\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GameStop +12% on buyout buzz</a></h4><ul> <li>GameStop (NYSE:<a href='https://seekingalpha.com/symbol/GME' title='GameStop Corp.'>GME</a>) is now<font color=\"green\"> up 12.22%</font> after the <em>WSJ</em> buyout report brings in new buyers.</li> <li>Also of interest this morning, Jefferies is out with a positive note in which the firm speculates that a GameStop acquisition could go off in the $17 to $25 range. The 52-week high on GameStop is $20.31.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3420618-gamestop-watch-wsj-buyout-report\" target=\"_blank\">GameStop on watch after WSJ buyout report</a> (Jan. 4)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3420714\" data-linked=\"GameStop +12% on buyout buzz\" data-tweet=\"$GME - GameStop +12% on buyout buzz https://seekingalpha.com/news/3420714-gamestopplus-12-on-buyout-buzz?source=tweet\" data-url=\"https://seekingalpha.com/news/3420714-gamestopplus-12-on-buyout-buzz\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>30&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420712\" data-ts=\"1546615836\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420712-natural-gas-inventory-draw-less-consensus\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Natural gas inventory draw less than consensus</a></h4><ul><li><a href=\"http://ir.eia.gov/ngs/ngs.html\" target=\"_blank\">EIA Natural Gas Inventory:</a> <strong>-20 Bcf</strong> vs. -47 Bcf consensus, -48 Bcf last week.</li><li>Futures <font color=\"green\">+1.12%</font> to $2.978.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/UNG' title='The United States Natural Gas ETF, LP'>UNG</a>, <a href='https://seekingalpha.com/symbol/DGAZ' title='VelocityShares 3x Inverse Natural Gas ETN'>DGAZ</a>, <a href='https://seekingalpha.com/symbol/UGAZ' title='VelocityShares 3x Long Natural Gas ETN'>UGAZ</a>, <a href='https://seekingalpha.com/symbol/BOIL' title='ProShares Ultra Bloomberg Natural Gas ETF'>BOIL</a>, <a href='https://seekingalpha.com/symbol/KOLD' title='ProShares UltraShort Bloomberg Natural Gas ETF'>KOLD</a>, <a href='https://seekingalpha.com/symbol/UNL' title='The United States 12 Month Natural Gas ETF, LP'>UNL</a> en</li></ul><div class=\"tiny-share-widget\" data-id=\"3420712\" data-linked=\"Natural gas inventory draw less than consensus\" data-tweet=\"$UNG $DGAZ $UGAZ - Natural gas inventory draw less than consensus https://seekingalpha.com/news/3420712-natural-gas-inventory-draw-less-consensus?source=tweet\" data-url=\"https://seekingalpha.com/news/3420712-natural-gas-inventory-draw-less-consensus\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420711\" data-ts=\"1546615778\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KLAC\" target=\"_blank\">KLAC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420711-report-chinese-rival-objections-to-kla-tencor-orbotech-tie-up\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Report: Few Chinese rival objections to KLA-Tencor/Orbotech tie-up</a></h4><ul>   <li>With KLA-Tencor (<a href=\"http://seekingalpha.com/symbol/KLAC\" target=\"_blank\">KLAC</a> <font color=\"green\">+3.2%</font>) in deep talks with China's government over an acquisition of Orbotech (<a href=\"http://seekingalpha.com/symbol/ORBK\" target=\"_blank\">ORBK</a> <font color=\"green\">+1.1%</font>), it's not running into large-company opposition on the tie-up, Dealreporter says.</li>    <li>While smaller rivals have raised concerns, there's no issues coming from the companies' two major Chinese clients: Semiconductor Manufacturing International Corp (<a href=\"http://seekingalpha.com/symbol/SMI\" target=\"_blank\">SMI</a> <font color=\"green\">+0.7%</font>) and BOE Technology.</li>    <li>KLA-Tencor recently refiled for approval on the deal.</li>    <li>Source: Bloomberg</li> </ul><div class=\"tiny-share-widget\" data-id=\"3420711\" data-linked=\"Report: Few Chinese rival objections to KLA-Tencor/Orbotech tie-up\" data-tweet=\"$KLAC $KLAC $ORBK - Report: Few Chinese rival objections to KLA-Tencor/Orbotech tie-up https://seekingalpha.com/news/3420711-report-chinese-rival-objections-to-kla-tencor-orbotech-tie-up?source=tweet\" data-url=\"https://seekingalpha.com/news/3420711-report-chinese-rival-objections-to-kla-tencor-orbotech-tie-up\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420709\" data-ts=\"1546615625\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VAR\" target=\"_blank\">VAR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420709-varian-up-7-after-goldman-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Varian up 7% after Goldman upgrade</a></h4><ul><li>Varian Medical Systems (<a href='https://seekingalpha.com/symbol/VAR' title='Varian Medical Systems, Inc.'>VAR</a> <font color=\"green\">+6.7%</font>) is up on below-average volume the heels of an upgrade to Buy from Sell with a $129 (10% upside) price target at Goldman Sachs.</li><li>Analyst Isaac Ro cites low investor expectations, conservative guidance and an upside to consensus EPS estimates, adding that investors \"do not appear to appreciate\" the upside in China related to its quota for radiation oncology systems.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420709\" data-linked=\"Varian up 7% after Goldman upgrade\" data-tweet=\"$VAR - Varian up 7% after Goldman upgrade https://seekingalpha.com/news/3420709-varian-up-7-after-goldman-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3420709-varian-up-7-after-goldman-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:27 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420707\" data-ts=\"1546615070\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RYTM\" target=\"_blank\">RYTM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420707-rhythm-pharma-up-6-ahead-of-corporate-update-jpm19\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rhythm Pharma up 6% ahead of corporate update at JPM19</a></h4><ul><li>Thinly traded Rhythm Pharmaceuticals (<a href='https://seekingalpha.com/symbol/RYTM' title='Rhythm Pharmaceuticals, Inc.'>RYTM</a> <font color=\"green\">+5.9%</font>) is up in early trade, albeit on only ~12,000 shares, following its <a href=\"https://seekingalpha.com/pr/17370469-rhythm-pharmaceuticals-outline-expected-2019-milestones-review-updated-clinical-data-bardet\" target=\"_blank\">announcement </a>of 2019 milestones and updated clinical data on setmelanotide that will be presented on Thursday, January 10, at JPM19.</li><li>Updated results from its Phase 2 basket studies evaluating setmelanotide in patients with Bardet-Biedl Syndrome &#40;BBS&#41; showed clinically meaningful weight loss after 41 - 47 weeks of treatment and significant reductions in hunger scores in two patients. Six of nine patients have lost 10% of their weight from baseline. Enrollment of at least 20 BBS patients and six Alström syndrome patients should be completed in H2.</li><li>Top-line data from its Phase 3 studies of setmelanotide in POMC and LEPR deficiency obesity should be available in Q3. If all goes well, a U.S. marketing application will follow in Q4/Q1 2020.</li><li>#JPM19</li></ul><div class=\"tiny-share-widget\" data-id=\"3420707\" data-linked=\"Rhythm Pharma up 6% ahead of corporate update at JPM19\" data-tweet=\"$RYTM - Rhythm Pharma up 6% ahead of corporate update at JPM19 https://seekingalpha.com/news/3420707-rhythm-pharma-up-6-ahead-of-corporate-update-jpm19?source=tweet\" data-url=\"https://seekingalpha.com/news/3420707-rhythm-pharma-up-6-ahead-of-corporate-update-jpm19\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420705\" data-ts=\"1546614671\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/M\" target=\"_blank\">M</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420705-macys-and-kohls-drop-on-december-trends-warning\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Macy&#39;s and Kohl&#39;s drop on December trends warning</a></h4><ul><li>Macy's (<a href='https://seekingalpha.com/symbol/M' title='Macy&#39;s Inc.'>M</a> <font color=\"red\">-2.4%</font>) and Kohl's (<a href='https://seekingalpha.com/symbol/KSS' title='Kohl&#39;s Corporation'>KSS</a> <font color=\"red\">-1.6%</font>) both track lower after Cleveland Research warns on December trends.</li><li>The research firm frequently causes ripples in the retail sector through its probing channel checks.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3420705\" data-linked=\"Macy&#39;s and Kohl&#39;s drop on December trends warning\" data-tweet=\"$M $M $KSS - Macy&#39;s and Kohl&#39;s drop on December trends warning https://seekingalpha.com/news/3420705-macys-and-kohls-drop-on-december-trends-warning?source=tweet\" data-url=\"https://seekingalpha.com/news/3420705-macys-and-kohls-drop-on-december-trends-warning\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420703\" data-ts=\"1546614462\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LNDC\" target=\"_blank\">LNDC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420703-landec-down-4-post-q2-result-lowers-fy-eps-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Landec down 4% post Q2 result; lowers FY EPS guidance</a></h4><ul><li>Landec (<a href='https://seekingalpha.com/symbol/LNDC' title='Landec Corporation'>LNDC</a> <font color=\"red\">-4%</font>) reported Q2 revenue growth of 2% Y/Y to $124.91M, reflecting 9.5% Y/Y increase in revenues at Lifecore and 1% Y/Y increase in Natural Foods revenues.</li><li>Q2 Gross margin <font color=\"green\">expanded by 110 bps</font> to 13.3%.</li><li>Segment gross margins: Natural foods <font color=\"green\">improved by 101 bps</font> to 9.9% and Lifecore <font color=\"red\">declined by 21 bps</font> to 36.7%.</li><li>Q2 Expenses: R&amp;D $2.53M (-24.9% Y/Y) and SG&amp;A $14.67M (+19.8% Y/Y).</li><li><strong>3Q19 Guidance: </strong>Revenue $156-159M and EPS $0.03-0.04.</li><li><strong>FY19 Guidance:</strong> Revenue growth 6-8%; EPS $0.25-0.29 (from $0.45-0.50, after accounting for the projected loss from the acquisition of Yucatan); cash flow from operations $26-30M and Capex $40-45M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3420526-landec-eps-line-misses-revenue\" target=\"_blank\">Landec EPS in-line, misses on revenue</a> (Jan. 3)</li></ul><div class=\"tiny-share-widget\" data-id=\"3420703\" data-linked=\"Landec down 4% post Q2 result; lowers FY EPS guidance\" data-tweet=\"$LNDC - Landec down 4% post Q2 result; lowers FY EPS guidance https://seekingalpha.com/news/3420703-landec-down-4-post-q2-result-lowers-fy-eps-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3420703-landec-down-4-post-q2-result-lowers-fy-eps-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:07 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420701\" data-ts=\"1546614141\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FTNT\" target=\"_blank\">FTNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420701-fortinet-cyberark-cut-goldman\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fortinet, CyberArk cut at Goldman</a></h4><ul><li>Fortinet (NASDAQ:<a href='https://seekingalpha.com/symbol/FTNT' title='Fortinet, Inc.'>FTNT</a>) <font color=\"red\">sinks 2.9%</font> after Goldman Sachs analyst Gabriela Borges cuts rating to sell from buy and slashes her price target to a Street low of $59 from $95.</li><li>Cites \"heightened cyclical risk\" and an elevated valuation; foresees decelerating product revenue in next two years.</li><li>CyberArk (<a href='https://seekingalpha.com/symbol/CYBR' title='CyberArk Software Ltd.'>CYBR</a> <font color='green'>+1%</font>) cut to neutral from buy and price target trimmed to a Street low of $78 from $86 on more difficult Y/Y license growth comparisons and a \"more balanced\" risk/reward picture for 2019.</li><li>Source: Bloomberg First Word.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3405090-dougherty-and-co-steps-fortinet-sidelines-earnings\" target=\"_blank\">Dougherty &amp; Co steps off Fortinet sidelines after earnings</a> (Nov. 5, 2018)</li></ul><div class=\"tiny-share-widget\" data-id=\"3420701\" data-linked=\"Fortinet, CyberArk cut at Goldman\" data-tweet=\"$FTNT $FTNT $CYBR - Fortinet, CyberArk cut at Goldman https://seekingalpha.com/news/3420701-fortinet-cyberark-cut-goldman?source=tweet\" data-url=\"https://seekingalpha.com/news/3420701-fortinet-cyberark-cut-goldman\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420698\" data-ts=\"1546613906\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BPMC\" target=\"_blank\">BPMC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420698-blueprint-medicines-advancing-lead-candidate-avapritinib-sets-two-year-plan-shares-up-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Blueprint Medicines advancing lead candidate avapritinib, sets two-year plan; shares up 3%</a></h4><ul><li>Blueprint Medicines (<a href='https://seekingalpha.com/symbol/BPMC' title='Blueprint Medicines'>BPMC</a> <font color=\"green\">+2.7%</font>) <a href=\"https://seekingalpha.com/pr/17370499-blueprint-medicines-announces-2020-blueprint-global-business-strategy-outlines-key-corporate\" target=\"_blank\">announces </a>its two-year plan, \"2020 Blueprint,\" under which it expects to have two marketed products and at least four marketing applications in process in the U.S. and Europe by the end of 2020.</li><li>Registration trials, Phase 2 studies PIONEER and PATHFINDER, supporting lead candidate avapritinib in advanced and indolent systemic mastocytosis &#40;SM&#41; (rare disorder in which mast cells accumulate in the skin and internal organs) are underway.</li><li><strong>Avapritinib</strong>: U.S. marketing application to be filed in H1 for PDGFRA Exon 18-mutant gastrointestinal stromal tumors &#40;GIST&#41; and fourth-line GIST. Enrollment in Phase 3 VOYAGER study in third/fourth-line GIST to be completed in H2. Phase 2 in second-line GIST to launch in H2. U.S. marketing applications in third-line GIST  and advanced SM to be filed in 2020</li><li><strong>BLU-667</strong>: Updated data from Phase 1 ARROW study in RET-altered cancers to be released in H1. Phase 3 study in first-line RET-fusion non-small cell lung cancer &#40;NSCLC&#41; to launch in H2. U.S. marketing application for second-line RET-fusion NSCLC and second-line RET-mutant medullary thyroid cancer &#40;MTC&#41; to be filed in H1 2020.</li><li><strong>BLU-554</strong>: Enrollment in China to start in H1 in Phase 1 study in advanced hepatocellular carcinoma (liver cancer) (with CStone Pharmaceuticals). Phase 1 study of BLU-554 and CS-1001 (CStone's PD-L1 inhibitor) to launch in China in H2.</li><li><strong>BLU-782</strong>: Phase 1 study in healthy volunteers to start this quarter. A Phase 2 in fibrodysplasia ossificans progressiva (inherited disorder characterized by the gradual replacement of muscle and connective tissue with bone) to launch in H1 2020.</li><li>One new discovery program will be nominated this year.</li><li>#JPM19</li></ul><div class=\"tiny-share-widget\" data-id=\"3420698\" data-linked=\"Blueprint Medicines advancing lead candidate avapritinib, sets two-year plan; shares up 3%\" data-tweet=\"$BPMC - Blueprint Medicines advancing lead candidate avapritinib, sets two-year plan; shares up 3% https://seekingalpha.com/news/3420698-blueprint-medicines-advancing-lead-candidate-avapritinib-sets-two-year-plan-shares-up-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3420698-blueprint-medicines-advancing-lead-candidate-avapritinib-sets-two-year-plan-shares-up-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420694\" data-ts=\"1546613352\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QLYS\" target=\"_blank\">QLYS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420694-jmp-sets-qualys-to-outperform-on-new-product-cycles\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JMP sets Qualys to Outperform on new product cycles</a></h4><ul>    <li>Qualys (<a href=\"http://seekingalpha.com/symbol/QLYS\" target=\"_blank\">QLYS</a> <font color=\"green\">+3.8%</font>) should see positive catalysts from new products in the next two years, JMP Securities says in an upgrade to Market Outperform.</li>    <li>A recent price decline (shares <font color=\"red\">dropped 17.4%</font> over the past quarter) has made an attractive entry with \"several new product cycles getting under way and a compelling long-term strategic roadmap,\" the firm says. Qualys has invested to expand its portfolio and it's \"one of the few major plays on securing cloud infrastructure, which, in our view, represents a substantial opportunity that will attract investors.\" (h/t Bloomberg)</li>    <li>JMP's price target of $85 implies 18% upside.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3420694\" data-linked=\"JMP sets Qualys to Outperform on new product cycles\" data-tweet=\"$QLYS - JMP sets Qualys to Outperform on new product cycles https://seekingalpha.com/news/3420694-jmp-sets-qualys-to-outperform-on-new-product-cycles?source=tweet\" data-url=\"https://seekingalpha.com/news/3420694-jmp-sets-qualys-to-outperform-on-new-product-cycles\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:49 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420691\" data-ts=\"1546612941\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420691-stocks-jump-1_5-in-opening-action\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stocks jump more than 1.5% in opening action</a></h4><ul><li>All of the major averages are <font color=\"green\">higher by more than 1.5%</font> amid a global rally, and following <a href=\"https://seekingalpha.com/news/3420650-payrolls-soar-312k-december-unemployment-rate-rises-3_9-percent\" target=\"_blank\">blowout December jobs</a> numbers in the U.S.</li><li>The 10-year Treasury yield is up a full eight basis points to 2.64%.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420691\" data-linked=\"Stocks jump more than 1.5% in opening action\" data-tweet=\"Stocks jump more than 1.5% in opening action https://seekingalpha.com/news/3420691-stocks-jump-1_5-in-opening-action?source=tweet\" data-url=\"https://seekingalpha.com/news/3420691-stocks-jump-1_5-in-opening-action\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420681\" data-ts=\"1546612040\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ELGX\" target=\"_blank\">ELGX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420681-endologix-down-9-premarket-on-nellix-recall\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Endologix down 9% premarket on Nellix recall</a></h4><ul><li>Nano cap Endologix (NASDAQ:<a href='https://seekingalpha.com/symbol/ELGX' title='Endologix Inc'>ELGX</a>) is down <font color=\"red\">9%</font> premarket on light volume following its <a href=\"https://seekingalpha.com/pr/17370543-endologix-takes-decisive-action-optimize-patient-outcomes-ensuring-nellix-system-used-within\" target=\"_blank\">announcement </a>that it is recalling the existing inventory of its Nellix System, restricting access for use under a clinical protocol with pre-screened patients to ensure adherence to current indications.</li><li>The company is taking action after recent data showed suboptimal outcomes when the system was used outside of current instructions.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420681\" data-linked=\"Endologix down 9% premarket on Nellix recall\" data-tweet=\"$ELGX - Endologix down 9% premarket on Nellix recall https://seekingalpha.com/news/3420681-endologix-down-9-premarket-on-nellix-recall?source=tweet\" data-url=\"https://seekingalpha.com/news/3420681-endologix-down-9-premarket-on-nellix-recall\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:27 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420677\" data-ts=\"1546611772\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SFLY\" target=\"_blank\">SFLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420677-shutterflyplus-3_1-keybanc-boosts-to-overweight\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shutterfly +3.1% as KeyBanc boosts to Overweight</a></h4><ul>   <li>Shutterfly (NASDAQ:<a href='https://seekingalpha.com/symbol/SFLY' title='Shutterfly, Inc.'>SFLY</a>) is <font color=\"green\">up 3.1%</font> premarket after an upgrade to Overweight at KeyBanc, with an eye to \"retooled\" promotional strategy at the company.</li>    <li>Cutting free promotions \"may help offset some of the inherent weakness in the markets and we think that SFLY\u2019s scale gives it distinct competitive advantages,\" the firm says, while it notes Shutterfly's recent acquisition of Lifetouch could bring incremental revenue and cost synergies. (h/t Bloomberg)</li>    <li>The bank is on the low side of the Street with its price target of $55, which implies 33.5% upside.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3420677\" data-linked=\"Shutterfly +3.1% as KeyBanc boosts to Overweight\" data-tweet=\"$SFLY - Shutterfly +3.1% as KeyBanc boosts to Overweight https://seekingalpha.com/news/3420677-shutterflyplus-3_1-keybanc-boosts-to-overweight?source=tweet\" data-url=\"https://seekingalpha.com/news/3420677-shutterflyplus-3_1-keybanc-boosts-to-overweight\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420676\" data-ts=\"1546611630\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JACK\" target=\"_blank\">JACK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420676-jack-in-boxplus-3-after-new-agreement-jana\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jack In The Box +3% after new agreement with Jana</a></h4><ul> <li>Jack In The Box (NASDAQ:<a href='https://seekingalpha.com/symbol/JACK' title='Jack In The Box Inc.'>JACK</a>) amends its cooperation agreement with Jana Partners to extend the deadline to appoint two new directors until March 15.</li> <li>Shares of JACK are <font color=\"green\">up 3.13%</font> in premarket trading to $81.09 vs. a 52-week trading range of $74.19 to $102.45.</li> <li><a href=\"https://seekingalpha.com/filing/4292169\" target=\"_blank\">SEC Form 8-K</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3420676\" data-linked=\"Jack In The Box +3% after new agreement with Jana\" data-tweet=\"$JACK - Jack In The Box +3% after new agreement with Jana https://seekingalpha.com/news/3420676-jack-in-boxplus-3-after-new-agreement-jana?source=tweet\" data-url=\"https://seekingalpha.com/news/3420676-jack-in-boxplus-3-after-new-agreement-jana\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420673\" data-ts=\"1546611472\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APHB\" target=\"_blank\">APHB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420673-ampliphi-bio-up-45-premarket-on-merger-c3j-therapeutics\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AmpliPhi Bio up 45% premarket on merger with C3J Therapeutics</a></h4><ul><li>Nano cap AmpliPhi Biosciences (NYSEMKT:<a href='https://seekingalpha.com/symbol/APHB' title='AmpliPhi Biosciences Corp.'>APHB</a>) is up <font color=\"green\">45%</font> premarket on robust volume on the heels of its <a href=\"https://seekingalpha.com/pr/17370474-ampliphi-biosciences-c3j-therapeutics-agree-merge\" target=\"_blank\">announced merger</a> with privately held <a href=\"http://www.c3jtherapeutics.com/\" target=\"_blank\">C3J Therapeutics</a>, a developer of targeted antimicrobials.</li><li>A wholly owned subsidiary of AmpliPhi will merge with C3J in an all-stock transaction after which C3J stockholders will own 76% of the combined company and AmpliPhi stockholders will own 24%, accounting for a $10M investment by certain C3J investors.</li><li>The deal should close this quarter.</li><li>The companies will host a conference call on Monday, January 14, at 4:30 pm ET to discuss the tie-up.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420673\" data-linked=\"AmpliPhi Bio up 45% premarket on merger with C3J Therapeutics\" data-tweet=\"$APHB $ARMP - AmpliPhi Bio up 45% premarket on merger with C3J Therapeutics https://seekingalpha.com/news/3420673-ampliphi-bio-up-45-premarket-on-merger-c3j-therapeutics?source=tweet\" data-url=\"https://seekingalpha.com/news/3420673-ampliphi-bio-up-45-premarket-on-merger-c3j-therapeutics\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420671\" data-ts=\"1546611234\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RAD\" target=\"_blank\">RAD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420671-rite-aid-eyes-reverse-split\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rite Aid eyes reverse split</a></h4><ul> <li>Rite Aid (NYSE:<a href='https://seekingalpha.com/symbol/RAD' title='Rite Aid Corporation'>RAD</a>) says it received formal notification from the New York Stock       Exchange that it's no longer in       compliance with continued listing standard rules due to the sub-$1 share price.</li><li>The company intends to pursue measures to \"cure\" the share price       non-compliance, including a potential reverse stock split.</li><li>RAD  <font color=\"green\">+2.08%</font> premarket to  $0.76.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17370541-rite-aid-responds-notice-non-compliance-nyse-trading-share-price-listing-standard-rules\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3420671\" data-linked=\"Rite Aid eyes reverse split\" data-tweet=\"$RAD - Rite Aid eyes reverse split https://seekingalpha.com/news/3420671-rite-aid-eyes-reverse-split?source=tweet\" data-url=\"https://seekingalpha.com/news/3420671-rite-aid-eyes-reverse-split\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>203&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420666\" data-ts=\"1546610904\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMID\" target=\"_blank\">AMID</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420666-nvax-gme-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NVAX, GME among premarket gainers</a></h4><ul><li>American Midstream Partners, LP (NYSE:<a href='https://seekingalpha.com/symbol/AMID' title='American Midstream Partners, LP'>AMID</a>) <font color=\"green\">+27%</font> on revised <a href=\"https://seekingalpha.com/news/3420523-american-midstream-gets-revised-buyout-bid-arclight\" target=\"_blank\">buyout</a> from ArcLight.</li><li>GameStop (NYSE:<a href='https://seekingalpha.com/symbol/GME' title='GameStop Corp.'>GME</a>) <font color=\"green\">+9% </font>on WSJ <a href=\"https://seekingalpha.com/news/3420618-gamestop-watch-wsj-buyout-report\" target=\"_blank\">buyout report</a>.</li><li>Novavax (NASDAQ:<a href='https://seekingalpha.com/symbol/NVAX' title='Novavax, Inc.'>NVAX</a>) <font color=\"green\">+8%</font> on <a href=\"https://seekingalpha.com/news/3420522-novavax-10-percent-hours-positive-nanoflu-data\" target=\"_blank\">positive</a> NanoFlu data.</li><li>DBV Technologies S.A. (NASDAQ:<a href='https://seekingalpha.com/symbol/DBVT' title='DBV Technologies'>DBVT</a>) <font color=\"green\">+8%</font>.</li><li>Uxin (NASDAQ:<a href='https://seekingalpha.com/symbol/UXIN' title='Uxin'>UXIN</a>) <font color=\"green\">+7%</font>.</li><li>Denbury Resources (NYSE:<a href='https://seekingalpha.com/symbol/DNR' title='Denbury Resources Inc.'>DNR</a>) <font color=\"green\">+6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420666\" data-linked=\"NVAX, GME among premarket gainers\" data-tweet=\"$AMID $AMID $GME - NVAX, GME among premarket gainers https://seekingalpha.com/news/3420666-nvax-gme-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3420666-nvax-gme-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420664\" data-ts=\"1546610858\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FLXN\" target=\"_blank\">FLXN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420664-flxn-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FLXN among premarket losers</a></h4><ul><li>Flexion Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/FLXN' title='Flexion Therapeutics, Inc.'>FLXN</a>) <font color=\"red\">-10%</font> on <a href=\"https://seekingalpha.com/news/3420512-flexion-therapeutics-reports-preliminary-q4-results\" target=\"_blank\">reporting</a> preliminary Q4 results.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3420664\" data-linked=\"FLXN among premarket losers\" data-tweet=\"$FLXN - FLXN among premarket losers https://seekingalpha.com/news/3420664-flxn-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3420664-flxn-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:07 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420658\" data-ts=\"1546609800\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RARE\" target=\"_blank\">RARE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420658-ultragenyxs-dtx401-shows-positive-action-in-glycogen-storage-disease-shares-up-4-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ultragenyx&#39;s DTX401 shows positive action in glycogen storage disease; shares up  4% premarket</a></h4><ul><li>Ultragenyx Pharmaceutical (NASDAQ:<a href='https://seekingalpha.com/symbol/RARE' title='Ultragenyx Pharmaceutical Inc.'>RARE</a>) is up <font color=\"green\">4%</font> premarket, albeit on only 100 shares, following its <a href=\"https://seekingalpha.com/pr/17370559-ultragenyx-announces-positive-topline-results-first-cohort-phase-1-2-clinical-study-dtx401\" target=\"_blank\">announcement </a>of preliminary data from a Phase 1/2 trial evaluating gene therapy DTX401 in patients with <a href=\"https://ghr.nlm.nih.gov/condition/glycogen-storage-disease-type-i\" target=\"_blank\">glycogen storage disease type Ia</a>, an inherited disorder characterized by the build up of sugar (glycogen) in cells leading to impaired organ function.</li><li>Three patients in the lowest dose cohort all experienced improved glucose control and increased time to hypoglycemia (low blood sugar) during fasting while two experienced clinically meaningful improvements in time to hypoglycemia during a controlled fasting challenge.</li><li>No infusion-related adverse events and no serious treatment-related adverse events have been reported. All adverse events to date have been mild or moderate.</li><li>Enrollment is the second cohort will begin this month with interim data expected mid-year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420658\" data-linked=\"Ultragenyx&#39;s DTX401 shows positive action in glycogen storage disease; shares up  4% premarket\" data-tweet=\"$RARE - Ultragenyx&#39;s DTX401 shows positive action in glycogen storage disease; shares up 4% premarket https://seekingalpha.com/news/3420658-ultragenyxs-dtx401-shows-positive-action-in-glycogen-storage-disease-shares-up-4-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3420658-ultragenyxs-dtx401-shows-positive-action-in-glycogen-storage-disease-shares-up-4-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:50 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420655\" data-ts=\"1546609396\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420655-fed-boxed-in-after-super-strong-employment-numbers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fed boxed in after super-strong employment numbers?</a></h4><ul><li>Alongside <a href=\"https://seekingalpha.com/news/3420650-payrolls-sky-312k-december-ue-rate-3_9-percent\" target=\"_blank\">the unexpected 312K jobs added</a> in December, November's originally-reported 155K job gain was revised up to 176K, and October's originally-reported 237K gain was revised up to 274K.</li><li>The unemployment rate did jump to 3.9% in December from 3.7%, but this is likely due to a higher denominator - the labor force participation rate rose to 63.1% from 62.9%.</li><li>Average hourly earnings rose 0.4% vs. expectations for 0.3%. On a year-over-year basis, they gained 3.2% vs. 3.0% expected.</li><li>Average weekly hours were flat at 34.5.</li><li>The news seemingly puts the Fed in a bit of a box. The central bank is surely shaken by the rout in markets, and might like to pause or end the rate hike cycle, but today's wildly strong data says differently. S&amp;P 500 (NYSEARCA:<a href='https://seekingalpha.com/symbol/SPY' title='SPDR S&P 500 Trust ETF'>SPY</a>) futures have given back some gains since the 8:30 ET print, now <font color=\"green\">up just 1%</font>.</li><li>The 10-year Treasury yield is up 4.5 basis points to 2.60%. <a href='https://seekingalpha.com/symbol/TLT' title='iShares 20+ Year Treasury Bond ETF'>TLT</a> <font color=\"red\">-0.55%</font> premarket. Gold (NYSEARCA:<a href='https://seekingalpha.com/symbol/GLD' title='SPDR Gold Trust ETF'>GLD</a>) is <font color=\"red\">down 0.3%</font>, and the dollar (<a href='https://seekingalpha.com/symbol/UUP' title='Invesco DB USD Bullish ETF'>UUP</a>, <a href='https://seekingalpha.com/symbol/UDN' title='Invesco DB US Dollar Index Bearish ETF'>UDN</a>) is racing higher.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420655\" data-linked=\"Fed boxed in after super-strong employment numbers?\" data-tweet=\"$SPY $TLT $GLD - Fed boxed in after super-strong employment numbers? https://seekingalpha.com/news/3420655-fed-boxed-in-after-super-strong-employment-numbers?source=tweet\" data-url=\"https://seekingalpha.com/news/3420655-fed-boxed-in-after-super-strong-employment-numbers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>83&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420654\" data-ts=\"1546609367\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LW\" target=\"_blank\">LW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420654-lamb-weston-lifts-annual-guidance-after-strong-fq2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lamb Weston lifts annual guidance after strong FQ2</a></h4><ul> <li>Lamb Weston (NYSE:<a href='https://seekingalpha.com/symbol/LW' title='Lamb Weston Holdings, Inc.'>LW</a>) tops estimates after posting double-digit growth in <a href=\"https://seekingalpha.com/pr/17370553-lamb-weston-reports-fiscal-second-quarter-2019-results-updates-full-year-outlook\" target=\"_blank\">FQ2</a>.</li> <li>The company' adjusted EBITDA rose 18% to $223M during the quarter and income from operations was up 21% to $174M. Management says it expects the operating environment in North America to remain generally favorable for the remainder of FY19.</li> <li>Looking ahead, Lamb Weston expects full-year sales growth in a mid-to-high single digits range vs. the prior estimate of mid-single digits growth. Adjusted EBITDA of $870M to $880M is anticipated vs. $860M to $870M prior view.</li><li>CEP update: \"While we anticipate delivering solid sales and earnings results in the second half of fiscal 2019, our performance will moderate as we begin to lap strong prior year results, face increased cost inflation, ramp up investments in operating, sales and product innovation capabilities, and tackle the challenges arising from a historically poor potato crop in Europe.\"</li><li>Shares of Lamb Weston are <font color=\"green\">up 1.0%</font> premarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3420651-lamb-weston-beats-0_08-beats-revenue\" target=\"_blank\">Lamb Weston beats by $0.08, beats on revenue</a> (Jan. 4)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3420654\" data-linked=\"Lamb Weston lifts annual guidance after strong FQ2\" data-tweet=\"$LW - Lamb Weston lifts annual guidance after strong FQ2 https://seekingalpha.com/news/3420654-lamb-weston-lifts-annual-guidance-after-strong-fq2?source=tweet\" data-url=\"https://seekingalpha.com/news/3420654-lamb-weston-lifts-annual-guidance-after-strong-fq2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420652\" data-ts=\"1546608828\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MRKR\" target=\"_blank\">MRKR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420652-marker-therapeutics-up-12-premarket-after-pipeline-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Marker Therapeutics up 12% premarket after pipeline update</a></h4><ul><li>Thinly traded micro cap Marker Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/MRKR' title='Marker Therapeutics Inc'>MRKR</a>) is up <font color=\"green\">12% </font>premarket on light volume following its <a href=\"https://seekingalpha.com/pr/17370199-marker-therapeutics-provides-updates-lead-clinical-programs\" target=\"_blank\">update </a>on its clinical programs for its MultiTAA T cell therapies. Highlights:</li><li><strong>Lymphoma</strong>: 15 heavily pretreated patients have been treated in a Phase 1/2 study. The disease control rate (responders + stable cancer) is 67% (n=10/15) including six complete responders. No relapses and no cases of cytokine release syndrome have been observed.</li><li>Four of the six complete responders have remained in remission for 3 - 42 months post-infusion. The average duration of remission is over 26 months.</li><li><strong>Multiple myeloma</strong>: Interim data from a Phase 1/2 trial showed an initial 100% (n=10/10) disease control rate, including one complete responder and two partial responders, but three patients progressed after 3 - 7 months. Four patients continue to have stable cancer.</li><li><strong>Acute lymphoblastic leukemia</strong>: Preliminary Phase 1 data showed a complete response rate of 88% (n=7/8) over 1 - 22 months.</li><li><strong>Ovarian cancer</strong>: Enrollment completed in a Phase 2 trial evaluating TPIV200 as maintenance therapy in patients in their first remission after surgery and platinum-based chemo. Interim data should be available by year-end.</li><li><strong>Triple-negative breast cancer</strong>: Initial data from a dose-finding study of TPIV200 as maintenance therapy following first-line treatment showed a 96% (n=26/27) immune response rate.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420652\" data-linked=\"Marker Therapeutics up 12% premarket after pipeline update\" data-tweet=\"$MRKR - Marker Therapeutics up 12% premarket after pipeline update https://seekingalpha.com/news/3420652-marker-therapeutics-up-12-premarket-after-pipeline-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3420652-marker-therapeutics-up-12-premarket-after-pipeline-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420650\" data-ts=\"1546608643\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420650-payrolls-soar-312k-in-december-unemployment-rate-rises-to-3_9\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Payrolls soar 312K in December; unemployment rate rises to 3.9%</a></h4><ul><li><strong><a href=\"http://stats.bls.gov/news.release/empsit.htm\" target=\"_blank\">December Nonfarm Payrolls</a></strong><strong>:</strong> +312K vs. consensus +178K, +176K previous (revised from 155K).</li><li>Unemployment rate: 3.9% vs. 3.7% consensus, 3.7% previous.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420650\" data-linked=\"Payrolls soar 312K in December; unemployment rate rises to 3.9%\" data-tweet=\"Payrolls soar 312K in December; unemployment rate rises to 3.9% https://seekingalpha.com/news/3420650-payrolls-soar-312k-in-december-unemployment-rate-rises-to-3_9?source=tweet\" data-url=\"https://seekingalpha.com/news/3420650-payrolls-soar-312k-in-december-unemployment-rate-rises-to-3_9\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>172&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420638\" data-ts=\"1546607111\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FLKS\" target=\"_blank\">FLKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420638-flex-pharma-up-44-on-merger-salarius-pharmaceuticals\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Flex Pharma up 44% on merger with Salarius Pharmaceuticals</a></h4><ul> <li>Flex       Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/FLKS' title='Flex Pharma'>FLKS</a>) and Salarius       Pharmaceuticals, LLC, have <a href=\"https://seekingalpha.com/pr/17370416-flex-pharma-salarius-pharmaceuticals-announce-merger-agreement-accelerate-clinical\" target=\"_blank\">entered</a> into a merger agreement under which later will merge with a wholly-owned subsidiary of       Flex Pharma.</li>          <li>Upon the closing of the       transaction, Flex Pharma and Salarius stockholders will own ~19.9% and ~80.1%, respectively of the combined company.</li><li>Shareholders of Flex Pharma will also receive a right to receive warrants, allowing them to purchase       additional shares.</li>     <li>The merger is expected to close in H1 2019.</li><li>FLKS shares are up <font color=\"green\">44%</font> premarket.</li>          </ul><div class=\"tiny-share-widget\" data-id=\"3420638\" data-linked=\"Flex Pharma up 44% on merger with Salarius Pharmaceuticals\" data-tweet=\"$FLKS $SLRX - Flex Pharma up 44% on merger with Salarius Pharmaceuticals https://seekingalpha.com/news/3420638-flex-pharma-up-44-on-merger-salarius-pharmaceuticals?source=tweet\" data-url=\"https://seekingalpha.com/news/3420638-flex-pharma-up-44-on-merger-salarius-pharmaceuticals\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420633\" data-ts=\"1546606654\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MAR\" target=\"_blank\">MAR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420633-marriott-updates-on-database-breach\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Marriott updates on database breach</a></h4><ul> <li>Marriott International (NYSE:<a href='https://seekingalpha.com/symbol/MAR' title='Marriott International, Inc.'>MAR</a>) says it determined that the total number of guest records involved in the database security incident is less than the initial disclosure. The hotel operator also says the number of payment cards and passport numbers involved is a relatively small percentage of the overall total records involved.</li> <li>Marriott has identified approximately 383M records as the upper limit for the total number of guest records that were involved in the incident, down from an early estimate of 500M.  The company has concluded with a fair degree of certainty that information for fewer than 383M unique guests was involved, due to duplicate account records. Marriott also believes that approximately 5.25M unencrypted passport numbers were included in the information accessed by an unauthorized third party. There is no evidence that the unauthorized third party accessed the master encryption key needed to decrypt the encrypted passport numbers.</li>  <li>MAR  <font color=\"green\">+2.08%</font> premarket to  $103.86.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17370459-marriott-provides-update-starwood-database-security-incident\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3420633\" data-linked=\"Marriott updates on database breach\" data-tweet=\"$MAR - Marriott updates on database breach https://seekingalpha.com/news/3420633-marriott-updates-on-database-breach?source=tweet\" data-url=\"https://seekingalpha.com/news/3420633-marriott-updates-on-database-breach\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:57 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420632\" data-ts=\"1546606340\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NFLX\" target=\"_blank\">NFLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420632-goldman-sachs-dials-up-conviction-on-netflix\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Goldman Sachs dials up the conviction on Netflix</a></h4><ul> <li>Goldman Sachs <a href=\"https://www.cnbc.com/2019/01/04/goldman-says-netflix-is-one-of-its-favorite-trades-for-2019.html\" target=\"_blank\">adds</a> Netflix (NASDAQ:<a href='https://seekingalpha.com/symbol/NFLX' title='Netflix, Inc.'>NFLX</a>) to its Conviction Buy List of top-rated stocks after watching shares fall off 36% from their high.</li> <li>\"We continue to believe Netflix's investment in content, technology and distribution will continue to drive subscriber growth well above consensus expectations both in the U.S. and internationally,\" writes Goldman analyst Heath Terry.</li> <li>\"We believe the fourth quarter will only be the beginning of the payoff from Netflix's accelerating spend and increasingly robust Originals slate, and that consensus continues to significantly underestimate the financial impacts of these dynamics,\" he adds.</li> <li>Terry expects Netflix to turn to the high yield debt market in the near term to solve its cash burn issue, but sees positive cash flow by 2022.</li> <li>Shares of Netflix are <font color=\"green\">up 2.97%</font> in premarket trading to $279.45 vs. the 52-week trading range of $205.59 to $423.21.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3420632\" data-linked=\"Goldman Sachs dials up the conviction on Netflix\" data-tweet=\"$NFLX - Goldman Sachs dials up the conviction on Netflix https://seekingalpha.com/news/3420632-goldman-sachs-dials-up-conviction-on-netflix?source=tweet\" data-url=\"https://seekingalpha.com/news/3420632-goldman-sachs-dials-up-conviction-on-netflix\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>52&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420628\" data-ts=\"1546605569\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RPM\" target=\"_blank\">RPM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420628-rise-in-costs-weighs-on-rpm-in-fq2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rise in costs weighs on RPM in FQ2</a></h4><ul><li>Excluding restructuring and other charges, <a href='https://seekingalpha.com/symbol/RPM' title='RPM International Inc.'>RPM</a>'s adjusted EBIT was $126M and diluted EPS was $0.52, compared to prior-year second-quarter adjusted diluted EPS of $0.57.</li><li>FQ2 sales of $1.36B, improved 3.6% over prior year. By segment: Industrial +2.1%; Specialty +7.6%; Consumer +4.1%.</li><li>\"Like many manufacturers, our bottom line was impacted by a continued rise in costs for raw materials, freight, labor and energy, as well as adverse foreign exchange translation,\" stated CEO Frank Sullivan.</li><li><a href='https://seekingalpha.com/symbol/RPM' title='RPM International Inc.'>RPM</a> <font color=\"red\">-8.1%</font> premarket</li><li><a href=\"https://seekingalpha.com/news/3420598-rpm-misses-0_15-misses-revenue\" target=\"_blank\">FQ2 results</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3420628\" data-linked=\"Rise in costs weighs on RPM in FQ2\" data-tweet=\"$RPM - Rise in costs weighs on RPM in FQ2 https://seekingalpha.com/news/3420628-rise-in-costs-weighs-on-rpm-in-fq2?source=tweet\" data-url=\"https://seekingalpha.com/news/3420628-rise-in-costs-weighs-on-rpm-in-fq2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:39 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420621\" data-ts=\"1546604434\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NBRV\" target=\"_blank\">NBRV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420621-fda-accepts-nabrivas-marketing-application-for-fosfomycin-action-date-june-30\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA accepts Nabriva&#39;s marketing application for fosfomycin, action date June 30</a></h4><ul><li>Under Priority Review status, the FDA <a href=\"https://seekingalpha.com/pr/17370435-nabriva-therapeutics-announces-acceptance-new-drug-application-intravenous-contepo-treat\" target=\"_blank\">accepts for review</a> Nabriva Therapeutics' (NASDAQ:<a href='https://seekingalpha.com/symbol/NBRV' title='Nabriva Therapeutics'>NBRV</a>) marketing application seeking approval for CONTEPO (fosfomycin for injection) for the treatment of complicated urinary tract infections (cUTIs), including acute pyelonephritis (kidney infection).</li><li>The agency's action date is June 30.</li><li><strong>Update</strong>: Shares are up <font color=\"green\">10%</font> premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420621\" data-linked=\"FDA accepts Nabriva&#39;s marketing application for fosfomycin, action date June 30\" data-tweet=\"$NBRV - FDA accepts Nabriva&#39;s marketing application for fosfomycin, action date June 30 https://seekingalpha.com/news/3420621-fda-accepts-nabrivas-marketing-application-for-fosfomycin-action-date-june-30?source=tweet\" data-url=\"https://seekingalpha.com/news/3420621-fda-accepts-nabrivas-marketing-application-for-fosfomycin-action-date-june-30\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420618\" data-ts=\"1546604278\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GME\" target=\"_blank\">GME</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420618-gamestop-on-watch-after-wsj-buyout-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GameStop on watch after WSJ buyout report</a></h4><ul> <li>GameStop (NYSE:<a href='https://seekingalpha.com/symbol/GME' title='GameStop Corp.'>GME</a>) is higher in early trading after <em>The Wall Street Journal</em> reports a <a href=\"https://www.wsj.com/articles/as-videogame-market-shifts-gamestop-struggles-to-boost-sales-11546561467\" target=\"_blank\">buyout</a> deal could be announced by the middle part of February.</li> <li>Sycamore Partners and Apollo Global Management are two of the PE firms bidding for gaming retailer.</li> <li>Shares of GameStop are <font color=\"green\">up 3.78%</font> on light premarket volume.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3420618\" data-linked=\"GameStop on watch after WSJ buyout report\" data-tweet=\"$GME - GameStop on watch after WSJ buyout report https://seekingalpha.com/news/3420618-gamestop-on-watch-after-wsj-buyout-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3420618-gamestop-on-watch-after-wsj-buyout-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420615\" data-ts=\"1546603715\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EPZM\" target=\"_blank\">EPZM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420615-epizyme-on-go-tazemetostat-nda-in-q4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Epizyme on go with tazemetostat NDA in Q4</a></h4><ul><li>Epizyme (NASDAQ:<a href='https://seekingalpha.com/symbol/EPZM' title='Epizyme'>EPZM</a>) <a href=\"https://seekingalpha.com/pr/17370388-epizyme-announces-registration-path-tazemetostat-follicular-lymphoma-provides-pipeline\" target=\"_blank\">announces </a>that, based on FDA feedback, it expects to file its U.S. marketing application for tazemetostat for EZH2 mutation-positive and wild-type relapsed/refractory follicular lymphoma &#40;FL&#41; in Q4. Data from the ongoing Phase 2 study will support the application.</li><li>A NDA submission for tazemetostat in epitheloid sarcoma should be filed next quarter. If approved, the company plans to commercialize in the U.S. on its own.</li><li>Pipeline update:</li><li>Combo study comparing tazemetostat to Roche's Rituxan (rituximab) and Celgene's Revlimid (lenalidomide) in relapsed/refractory FL should launch this year.</li><li>Company is exploring additional opportunities for the combination of tazemetostat and the chemo regimen R-CHOP in FL.</li><li>A combo study in castration-resistant prostate cancer should launch mid-year. Assessment in platinum-resistant cancers should start in H2.</li><li>The company and Roche's (<a href='https://seekingalpha.com/symbol/RHHBY' title='Roche Holding Ltd ADR'>OTCQX:RHHBY</a>) Genentech have decided not to move forward with a study of tazemetostat and Tecentriq (atezolizumab) non-small cell lung cancer &#40;NSCLC&#41;.</li><li>On the capital front, its current resources should be sufficient to fund operations into Q2 2020.</li><li>Management will host a conference call this morning at 8:30 am ET to discuss its corporate update.</li><li><strong>Update</strong>: Shares are up <font color=\"green\">23%</font> premarket on modest volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420615\" data-linked=\"Epizyme on go with tazemetostat NDA in Q4\" data-tweet=\"$EPZM $EPZM $RHHBY - Epizyme on go with tazemetostat NDA in Q4 https://seekingalpha.com/news/3420615-epizyme-on-go-tazemetostat-nda-in-q4?source=tweet\" data-url=\"https://seekingalpha.com/news/3420615-epizyme-on-go-tazemetostat-nda-in-q4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}